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1 Purpose of the manual
This manual is a companion to ‘The ASSIST-
linked brief intervention for hazardous and 
harmful substance use: manual for use in 
primary care’1 and is based on ‘The Alcohol, 
Smoking and Substance Involvement Screening 
Test (ASSIST): Guidelines for Use in Primary 
Care. Draft Version 1.1 for Field Testing’2. The 
purpose of this manual is to introduce the 
ASSIST and to describe how to use it in health 
care settings – particularly community based 
primary health care settings – to identify peo-
ple who are using substances, so that a brief 
intervention (or referral) can be provided,  
as appropriate.
The manual will describe:
❙❙ rationale for screening and brief intervention;
❙❙ problems related to substance use;
❙❙ the development and validation of the ASSIST;
❙❙ how to use the ASSIST (administration, scor-
ing and interpretation of scores);
❙❙ motivational interviewing tips to facilitate the 
process of asking about substance use;
❙❙ how to incorporate ASSIST screening in 
everyday practice.
Additional information is included in the 
Appendices to the manual:
❙❙ Appendix A includes a copy of the ASSIST 
questionnaire.
❙❙ Appendix B includes a copy of the ASSIST 
response card for clients.
❙❙ Appendix C includes a copy of the ASSIST 
feedback report card for clients.
❙❙ Appendix D includes a copy of the risks of 
injecting card for clients.
❙❙ Appendix E provides information about how to 
adapt the ASSIST for other languages and cul-
tures and to take account of the local situation.
❙❙ Appendix F provides answers to the self-
testing questions posed in Chapter 11 
‘Good practice in ASSIST questionnaire 
administration’.
❙❙ Appendix G provides two scripted ASSIST 
examples for practice in role play.
A companion document ‘The ASSIST-linked 
brief intervention for hazardous and harmful 
substance use: manual for use in primary care’1 
explains how to link the ASSIST to a brief 
intervention to help clients reduce or stop their 
substance use.
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2 What is the ASSIST?
The Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST) was 
developed under the auspices of the World 
Health Organization (WHO) by an international 
group of addiction researchers and clinicians 
in response to the overwhelming public health 
burden associated with psychoactive substance 
use worldwide3, 4, 5. It was designed to be 
used in primary health care settings where 
hazardous and harmful substance use among 
clients may go undetected, or become worse. 
The ASSIST (version 3.1) is an 8 item 
questionnaire designed to be administered by a 
health worker to a client using paper and pencil, 
and takes about 5-10 minutes to administer. The 
ASSIST was designed to be culturally neutral and 
useable across a variety of cultures to screen for 
use of the following substances: 
❙❙ tobacco products 
❙❙ alcohol
❙❙ cannabis
❙❙ cocaine
❙❙ amphetamine-type stimulants (ATS) 
❙❙ sedatives and sleeping pills (benzodiazepines)
❙❙ hallucinogens
❙❙ inhalants
❙❙ opioids 
❙❙ ‘other’ drugs
A list of the types of substances that fall into 
these categories, including some common 
street names, can be found in Box 3.
The ASSIST determines a risk score for each 
substance which is used to start a discussion 
(brief intervention) with clients about their 
substance use. The score obtained for each 
substance falls into a ‘lower‘, ‘moderate’ or 
‘high’ risk category which determines the most 
appropriate intervention for that level of use 
(‘no treatment’, ‘brief intervention’ or ‘referral 
to specialist assessment and treatment’ 
respectively).
The ASSIST obtains information from clients 
about lifetime use of substances, and use of 
substances and associated problems over the last 
3 months. It can identify a range of problems 
associated with substance use including acute 
intoxication, regular use, dependent or ‘high 
risk’ use and injecting behaviour.
In brief the ASSIST comprises the following 
questions:
❙❙ Question 1 (Q1) asks about which substances 
have ever been used in the client’s lifetime.
❙❙ Question 2 (Q2) asks about the frequency of 
substance use in the past three months, which 
gives an indication of the substances which 
are most relevant to current health status.
❙❙ Question 3 (Q3) asks about the frequency 
of experiencing a strong desire or urge to use 
each substance in the last three months.
❙❙ Question 4 (Q4) asks about the frequency of 
health, social, legal or financial problems relat-
ed to substance use in the last three months.
❙❙ Question 5 (Q5) asks about the frequency 
with which use of each substance has 
interfered with role responsibilities in the 
past three months.
❙❙ Question 6 (Q6) asks if anyone else has ever 
expressed concern about the client’s use of 
each substance and how recently that occurred.
❙❙ Question 7 (Q7) asks whether the client has 
ever tried to cut down or stop use of a sub-
stance, and failed in that attempt, and how 
recently that occurred.
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❙❙ Question 8 (Q8) asks whether the client has 
ever injected any substance and how recently 
that occurred.
The ASSIST v3.1 questonnaire can be found in 
the Appendix A, and more information about 
how to administer it and ask each question can 
be found in Chapter 12 on ‘How to administer 
the ASSIST questionnaire‘. Two scripted prac-
tice examples for role play also are provided in 
Appendix G. 
Taken together these questions provide an 
indication of the level of risk associated with 
the client’s substance use, and whether use 
is hazardous and likely to be causing harm 
(now or in the future) if use continues. Scores 
in the mid range on the ASSIST are likely to 
indicate hazardous or harmful substance use 
(‘moderate risk’) and higher scores are likely 
to indicate substance dependence (‘high 
risk’). Questions particularly associated with 
dependent or ‘high risk’ use are: compulsion to 
use (Q3), failed attempts to cut down (Q7) and 
injecting behaviour (Q8). 
Scoring is done by adding scores of questions 
2 to 7. Responses to Q8 are not included in cal-
culating specific substance involvement score 
but injecting is an indicator of risk. Injecting 
behaviour (Q8) is a particularly high risk activity 
associated with increased likelihood of over-
dose, dependence, infection with bloodborne 
viruses such as HIV and hepatitis C and with 
higher levels of other drug related problems. 
If a client has been frequently injecting in the 
last 3 months then they may require referral 
to specialist assessment and treatment. More 
information on this is provided in Chapters 14 
and 15 of this manual.
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3 Development of the ASSIST and linked brief intervention
The development of the ASSIST builds on 
previous work by WHO to advance alcohol 
screening and brief intervention through the 
development, validation and promotion of 
the Alcohol Use Disorders Identification Test 
(AUDIT)6, 7, 8. The success of the AUDIT project 
in promoting alcohol screening and brief 
intervention and its effectiveness in reducing 
alcohol-related problems in primary health care 
settings provided the impetus for the extension 
of screening and brief intervention to other 
substances and related problems, and the 
methods used provided a model for the WHO 
ASSIST project9. 
The limitations of using existing screening tests 
in primary care settings have recently been 
outlined by McPherson and Hersh (2000)10 and 
Babor (2005)11. Many existing instruments, 
such as the Addiction Severity Index (ASI)12, 
and expanded Substance Abuse Module of the 
Composite International Diagnostic Interview 
(CIDI-SAM)13 although comprehensive, are time 
consuming to administer in primary care set-
tings. On the other hand, some of the briefer 
instruments available, such as the CAGE-
Adapted to Include Drugs (CAGE-AID)14, have 
a focus on dependence, which is less useful 
for detecting harmful or hazardous use in non-
dependent persons. Moreover, the available 
self-report screening tests have a number of 
limitations from a cross-cultural perspective. 
Most were developed in the United States of 
America and do not have demonstrated sen-
sitivity and specificity for use in other cultures 
and have not been extensively validated.
In 1997 WHO developed the ASSIST to:
❙❙ be faster to administer than existing diagnos-
tic tests for substance use and substance use 
disorders;
❙❙ screen for all psychoactive substances, not 
just alcohol or tobacco;
❙❙ be able to be used in Primary Health Care 
settings;
❙❙ have cross cultural relevance;
❙❙ be able to link easily into a brief intervention.
The ASSIST has been through three main 
phases of testing to ensure that it is a reliable 
and valid instrument in international settings, 
and able to link into a brief intervention.
Phase I of the WHO ASSIST project was 
conducted in 1997 and 19983. It involved 
the development of the first version of the 
ASSIST (version 1.0). The draft questionnaire 
had 12 items. The reliability and feasibility of 
the questionnaire items were assessed in a 
test-retest reliability study which was carried 
out in Australia, Brazil, India, Ireland, Israel, the 
Palestinian Self-Rule Areas, Puerto Rico, the 
United Kingdom of Great Britain and Northern 
Ireland and Zimbabwe. The sites were chosen 
to ensure that study participants would be 
culturally diverse and have different substance 
use patterns. The results showed that the 
ASSIST had good reliability and feasibility, and 
was revised to an 8 item questionnaire (version 
2.0) on the basis of feedback from the study 
participants to ensure that all items were easy 
to administer and understand.
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Phase II of the project was an international 
study to validate the ASSIST questionnaire 
in a variety of primary health care and drug 
treatment settings. Validity investigates 
whether a test is measuring the constructs 
and conditions intended to be measured. 
The study took place during 2000 and 2002 
and was carried out in Australia, Brazil, India, 
Thailand, the United Kingdom, the United 
States of America and Zimbabwe. Participants 
were recruited from both primary care and 
alcohol and drug treatment services to ensure 
that individuals with different substance 
use patterns were adequately represented. 
The study demonstrated that the ASSIST 
had good concurrent, construct, predictive 
and discriminant validity, including the 
development of cut-off scores for ‘lower’, 
‘moderate’ and ‘high’ risk3, 15, 16. The resulting 
questionnaire ASSIST v3.0 was finally revised 
to the ASSIST v3.1 for clinical use in health and 
welfare settings whereas the version 3.0 is 
advised to be used for research purposes.  
A pilot study also conducted at the same 
time demonstrated that participants recruited 
from primary health care settings did reduce 
their substance use if given a brief intervention 
related to their ASSIST scores.
Phase III of the study consisted of a randomized 
controlled trial investigating the effectiveness 
of a brief intervention linked to ASSIST 
scores for moderate risk cannabis, cocaine, 
amphetamine-type stimulant or opioid use5. 
Participants were recruited from primary health 
care settings and scored within the moderate 
risk range for at least one of these substances. 
The study was conducted between 2003 and 
2007 in Australia, Brazil, India and the USA. 
The brief intervention lasted between 5 and 
15 minutes and was based on the FRAMES 
model17 and incorporated Motivational 
Interviewing techniques18. It focused on the 
delivery of personalised feedback regarding the 
participant’s ASSIST scores and associated risk 
through the use of a purpose-designed ASSIST 
feedback report card (see Appendix C). The brief 
intervention was bolstered with take-home 
self-help information19. The results showed 
that participants receiving a brief intervention 
for illicit substances had significantly reduced 
ASSIST scores after 3 months compared with 
control participants who did not receive a 
brief intervention for their substance use. 
Moreover, over 80% of participants reported 
attempting to cut down on their substance use 
after receiving the brief intervention and also 
provided positive comments on the impact of 
the brief intervention5.
Information on how to link a brief intervention 
into ASSIST scores can be found in ‘The 
ASSIST-linked brief intervention for hazardous 
and harmful substance use: manual for use in 
primary care’1.
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4 Rationale for screening for substance use
There is a significant public health burden 
attributable to psychoactive substance use 
worldwide. Estimates from 2004,  indicate that 
tobacco, alcohol and illicit drugs account for 
8.7%, 3.8% and 0.4% of all deaths respectively, 
and 3.7%, 4.5% and 0.9% of Disability 
Adjusted Life Years (DALYs) lost respectively. 
According to the 2009 Global Health Risks 
report, substance use is among the top 20 risk 
factors for death and disability worldwide20. 
Hazardous and harmful alcohol and other 
substance use also are risk factors for a wide 
variety of social, financial, legal and relationship 
problems for individuals and their families. 
Globally, there is an increasing trend for people 
to use multiple substances, either together or at 
different times, which is likely to further increase 
the risks. 
Substance use and associated risks fall on a 
continuum ranging from ‘lower risk’ (occasional 
or non-problematic use) to ‘moderate risk’ 
(more regular use) to ‘high risk’ (frequent 
high-risk use). ‘High risk’ or dependent users 
are more easily identified by clinicians than 
those at lower or moderate risk from their 
substance use. While it is clear that dependent 
use is associated with a significant burden of 
disease, there is also evidence that the burden 
on health care systems from non-dependent, 
but harmful or hazardous use, may be greater 
than the burden due to dependent use21, 22. 
Accordingly, the ASSIST questionnaire has been 
designed specifically to identify and intervene 
with people who are using substances in a 
hazardous way that may be creating harms, 
including the risk of progressing to dependence.
Screening aims to detect health problems or 
risk factors at an early stage before they have 
caused serious disease or other problems, and is 
part of maintaining prevention practice activities 
in health care settings23, 24. The WHO has identi-
fied a number of criteria for deciding which 
medical conditions are suitable for screening 
(see Box 1).
Hazardous and harmful use of psychoactive 
substances meets all these criteria and screen-
ing for substance use can be seen as an exten-
sion of existing screening activities in primary 
health care.
BOx 1 | Criteria for screening
❙❙ The condition is a significant problem affecting 
the health and wellbeing of individuals and  
the community.
❙❙ There are acceptable treatments or interventions 
available for clients who screen positive.
❙❙ Early identification and intervention leads to 
better outcomes than later treatment.
❙❙ There is a suitable screening test available 
which is acceptable to clients.
❙❙ The screening test must be available at a 
reasonable cost.
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5 Who can use the ASSIST?
The ASSIST is designed to be used by primary 
health care workers, but has been found to 
be useful for any human services worker who 
may come into contact with people who use 
substances in a harmful or hazardous way in 
their line of work, or who work with people 
whose substance use may place them at 
increased risk of harms compared with the rest 
of the community. These include: community 
health workers, mental health workers, nurses, 
social workers, physicians, general practitioners, 
psychologists, youth workers, indigenous 
workers, psychiatrists, obstetricians, midwives, 
counsellors, correctional service officers and 
drug and alcohol workers. The remainder of 
this manual will use the term ‘health worker’ to 
denote all of these service personnel.
Primary health care workers, in particular, have 
the opportunity to screen a broad range of 
people for general lifestyle issues as a routine 
part of their health care service and are a 
trusted and credible source of information. 
In developed countries, up to 85% of people 
see a primary health care worker at least once 
per year. Clients with problems related to 
psychoactive substance use are likely to have 
more frequent consultations. Screening at the 
primary care level may increase the likelihood 
of identifying individuals using substances in 
a non-dependent, but harmful or hazardous 
way, who are more likely to respond well to an 
intervention. Many common health problems 
seen in primary health care settings may be 
made worse by psychoactive substance use, and 
screening provides an opportunity to educate 
clients about the risks of hazardous alcohol or 
other substance use. There is evidence that 
if primary health care workers inquire about 
substance use risk factors then clients are more 
willing to talk about substance use problems 
and to consider the possibility of changing their 
substance use behaviours.
For most people, the ASSIST can be completed 
in about five or ten minutes and can be 
incorporated into the normal consultation. 
Alternatively, it may be administered by 
another staff member while the client is 
waiting to see the health worker. In the future, 
it is possible that certain clients may be able to 
self-complete a customised electronic version 
of the ASSIST, but as yet the ASSIST has not 
been validated for self completion by clients.
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6 Which clients should be screened?
The ASSIST can be used in a number of ways 
to assess clients’ substance use. In an ideal 
world, all primary health care clients would be 
screened annually for substance use as part 
of a health promotion screening programme. 
This is particularly important for settings where 
a higher proportion of clients are likely to be 
substance users compared with the rest of 
the community. For example, university health 
services, sexually transmitted disease clinics, 
districts with a high prevalence of sex workers, 
mental health services, prisoner assessment 
programs and primary health services in other 
locations with a high prevalence of substance 
use (see Box 2). If health workers screen 
only those they think are likely to have a 
substance use problem, they may miss clients 
with hazardous and harmful substance use. 
Guidelines for how to set up a screening 
programme in health settings are presented 
later in this manual.
Substance use generally commences during 
adolescence and this period can be seen as a 
critical milestone for substance use problems 
and an appropriate time to commence screen-
ing young clients. The exact age at which it is 
appropriate to commence regular screening 
for substance use will vary depending on local 
prevalence and patterns of use. It is important 
to be aware of the legal age of consent in the 
jurisdiction where the instrument will be used 
and the legal requirements relating to screen-
ing and intervention with adolescents who are 
under such age. 
However, it is important to note that at this 
time the ASSIST has only been validated for 
use in an adult population (between 18 and 
60 years of age). The ASSIST has shown good 
cross-cultural neutrality and is likely to be feasi-
ble for use with adolescents. However, the style 
and content of the current instrument as well 
as the cut-off scores that determine whether 
a client is ‘lower’, ‘moderate’ or ‘high’ risk may 
not be appropriate for use with adolescents. 
For example, an adult who consumes alcohol 
at low-risk levels on a weekly basis would score 
within the ‘lower risk’ category. An adolescent 
person drinking at these same levels may be at 
greater health and social risks and yet still be 
scoring within the ‘lower risk’ category.
BOx 2 | Who to screen
❙❙ Ideally, all clients in a health promotion 
screening programme commencing in young 
adulthood.
❙❙ Primary care and other health care settings 
likely to have a high proportion of substance 
users – e.g. STD clinics, university health 
services, health services in areas with high 
proportions of sex workers and mental health 
settings.
❙❙ Clients whose presenting complaint suggests 
it is/may be related to substance use.
❙❙ New prisoners, particularly those whose 
crimes may be associated with substance 
usea.
❙❙ Clients whose condition would be adversely 
affected by substance use.
❙❙ Pregnant womenb.
a Examples of crimes associated with substance use include: 
dealing, driving under the influence, violence while under the 
influence, stealing to fund substance use habits etc.
b While pregnant women are a high risk group, it is worth 
noting that the ASSIST has not been formally validated in this 
population as yet.
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7 Problems related to substance use
The ASSIST is the first screening test which 
covers all psychoactive substances including 
alcohol, tobacco and illicit drugs, and can 
help health care workers identify the level of 
associated risk for each substance used by a 
client. While substance use is associated with 
physical and mental health problems, it is also 
worth noting that harmful or hazardous use 
patterns of alcohol and drugs can also cause 
significant social problems for the user, such as 
problems with family, friends, the law, work or 
study and finances.
Health care workers should be aware that there 
are several reasons people use psychoactive 
substances. Many people use substances 
because they have pleasurable or desirable 
effects for the user, while others may use 
them to block out physical or psychological 
pain. Substance use may also serve some 
other function or purpose. For example, 
psychostimulant users may use these substances 
to increase their performance, to stay awake or 
lose weight. However, substance use problems 
can arise as a result of acute intoxication, regular 
use or dependence, and from the way in which 
substances are used. It is possible for a person to 
have problems from all of these. The ASSIST has 
been designed to detect problems relating to all 
the above-mentioned patterns of substance use. 
Acute intoxication
Problems relating to acute intoxication can 
occur as a result of a single episode of drug 
use and may include:
❙❙ acute toxic effects including ataxia, vomiting, 
fever and confusion
❙❙ overdose and loss of consciousness
❙❙ accidents and injury
❙❙ aggression and violence
❙❙ unintended sex and unsafe sexual practices
❙❙ unpredictable behaviour.
Regular use
A variety of different problems can occur 
from using substances regularly, ranging from 
physical problems to mental health and social 
problems. The kinds of problems relating to 
regular use include: 
❙❙ specific physical and mental health problems
❙❙ tolerance
❙❙ anxiety, depression, mood swings, irritability
❙❙ sleep problems
❙❙ financial difficulties
❙❙ criminal offences
❙❙ relationship problems
❙❙ difficulties with regular job or study
❙❙ cognitive problems relating to memory  
or attention.
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Dependent use
The problems arising from dependent use of 
a substance can be similar to those observed 
with regular use, but are more severe. 
Dependence is usually associated with more 
frequent use of a substance, and at higher 
doses than used previously. Associated 
problems include:
❙❙ marked tolerance
❙❙ severe physical and mental health problems
❙❙ increasingly dysfunctional in daily life
❙❙ craving and increased desire to use
❙❙ usual role obligations not fulfilled
❙❙ criminal behaviour
❙❙ relationship breakdowns
❙❙ difficulty stopping in spite of problems
❙❙ possible withdrawal symptoms on abstinence
❙❙ continued use despite evidence the use is 
causing harms to the individual.
Withdrawal symptoms vary depending on the 
drug involved but generally include craving 
(strong desire for the psychoactive substance or 
its effects), anxiety, irritability, gastrointestinal 
upsets and sleep problems. Symptoms are more 
severe for some drugs than others. Withdrawal 
from alcohol, benzodiazepines and opioids may 
require medical management while uncompli-
cated withdrawal from other drugs can usually 
be managed with supportive care. If a client is 
suspected to be experiencing withdrawal from 
a substance, administering the ASSIST may not 
be appropriate at that time. Given the sever-
ity and risk associated with some withdrawal 
syndromes, clients can be referred to a service 
where they can receive detailed clinical assess-
ment and treatment if required.
Risks of injecting
Injecting of any drug is a significant risk factor 
and is associated with a number of risks as 
outlined below:
❙❙ dependence
❙❙ overdose
❙❙ psychosis
❙❙ vein collapse
❙❙ infection
❙❘ local
❙❘ abscesses & ulcers
❙❘ systemic
❙❘ HIV
❙❘ hepatitis C
A resource that is available for health workers 
to give feedback to clients about injecting is the 
risks of injecting card (see Appendix D). All cur-
rent injecting clients should be given feedback 
about injecting behaviour using the card, includ-
ing enquiry into injecting behaviour and recom-
mendation for HIV and hepatitis testing.
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8 Specific health problems from individual substances
This chapter provides an overview of some of 
the specific health and other problems due 
to individual substances. The tables listing 
the associated health risks are taken from the 
ASSIST feedback report card (see Appendix C) 
which is used to provide feedback to clients as 
part of the brief intervention. It is important 
for health workers administering the ASSIST 
to have some knowledge of the health, 
social, legal and financial impacts of specific 
substances. This knowledge will be useful when 
administering Q4 of the ASSIST around health, 
social, legal and financial problems, and also 
when delivering the brief intervention.
While the health risks associated with substance 
use are the main focus here, it is worth noting 
that substance use is also associated with a 
range of social, legal and financial problems. 
Some of the impacts that are pertinent to 
particular clients may not be specifically listed 
here. For example, the criminogenic impact that 
substance use has caused for offenders within 
a prison population, or, the social and familial 
impacts that substance use may have caused 
for clients of family and child health services. 
Health workers administering the ASSIST and 
linked brief intervention should be aware of 
the impacts of substance use most relevant to 
their clientele and include them in the ASSIST 
and linked brief intervention where relevant.
Tobacco products
Use of tobacco products is a major public 
health problem and the leading cause of 
deaths attributable to psychoactive substance 
use globally. Smoking of tobacco products is 
a risk factor for a number of serious long term 
health problems and increases the severity or 
risk of complications of other health problems 
such as high blood pressure, diabetes and 
asthma. Children exposed to second-hand 
tobacco smoke are at increased risk of a range 
of health problems such as respiratory 
infections, allergies and asthma. Pregnant 
women who smoke are at higher risk of 
miscarriage, premature labour and having a low 
birth weight baby. While the majority of people 
consume tobacco via smoking, use of tobacco 
products by means other than smoking, such 
as chewing, or sniffing is also associated with 
increased risk of diseases. Finally, exposure to 
second-hand tobacco smoke also increases the 
risk of health problems among people who do 
not smoke themselves.
The risks associated with use of 
tobacco products include:
 Premature ageing and wrinkling of the skin
Low fitness and longer recovery times after 
having a cold or flu
Respiratory infections and asthma
High blood pressure and diabetes mellitus
Miscarriage, premature labour and low birth 
weight babies for pregnant women
Kidney disease
Chronic obstructive pulmonary diseases includ-
ing emphysema
Heart disease, stroke and vascular diseases
Cancers of lung, bladder, breast, mouth, 
throat and oesophagus
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Alcohol
Alcohol consumption is a risk factor for a wide 
range of health problems and harmful use of 
alcohol is a major cause of premature illness, 
disability and death. Social problems also 
are frequently associated with harmful or 
hazardous and dependent alcohol use and 
include breakdown of relationships with family 
and friends and difficulty maintaining study 
or work. For some people (men over 45 and 
women after menopause), low level alcohol 
consumption was shown to be associated (in 
studies undertaken in high-income countries) 
with some health benefits, mainly due to a 
reduction in risk for heart disease from middle 
age onwards. The lowest risk is associated with 
an average of 10g of alcohol per day for men 
and less than 10g of alcohol per day for women 
(as an example, one can of beer has 13g of 
alcohol; 100 ml of wine has approximately 9.5g 
of alcohol; 35 ml of a distilled spirit at 40% has 
11g of alcohol). Women who consume alcohol 
during pregnancy are at risk of having babies 
with birth defects, learning and behavioural 
difficulties and impaired brain development. 
Tolerance and dependence may develop as a 
result of regular drinking and dependent drinkers 
may suffer withdrawal symptoms if they reduce 
or stop their alcohol consumption. Severe alcohol 
withdrawal complicated by delirium tremens is 
a medical emergency. Withdrawal symptoms 
include tremor, sweating, anxiety, nausea, 
vomiting and diarrhoea, insomnia, headache, 
hypertension, hallucinations and convulsions. 
For more information on alcohol effects and risk 
levels for drinking see Babor et al. 20017. 
The risks associated with use of alcohol 
at unsafe levels include:   
 Hangovers, aggressive and violent behaviour, 
accidents and injury, nausea and vomiting
Reduced sexual performance and  
premature ageing
Digestive problems, ulcers, inflammation of 
the pancreas and high blood pressure
Anxiety and depression, relationship difficulties, 
and financial and work problems
Difficulty remembering things and  
solving problems
Birth defects and brain damage in babies of 
pregnant women
Permanent brain damage leading to memory 
loss, cognitive deficits and disorientation
Stroke, muscle and nerve damage
Liver and pancreas diseases
Cancers of the mouth, throat and breast
Suicide
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Cannabis
Cannabis is the most widely consumed illicit 
drug globally. While it is possible to experience 
cannabis overdose and toxicity, the likelihood 
of death due to cannabis intoxication alone 
is very low, although combination with other 
drugs can result in overdose and death. 
However, cannabis use is associated with 
numerous negative health consequences. 
Cannabis use in pregnancy has similar effects 
on mother and baby to tobacco smoking and 
can increase the severity and complications of 
existing disease conditions such as high blood 
pressure, heart disease, respiratory diseases 
and certain cancers.
The risks associated with use of  
cannabis include:
 Problems with attention and motivation
Anxiety, paranoia, panic and depression
Decreased memory and problem solving ability
High blood pressure
Asthma and bronchitis
Psychotic symptoms and psychoses particularly 
in those with a personal or family history of 
schizophrenia
Heart disease and chronic obstructive pul-
monary disease
Cancers of the upper airway and throat
Cocaine
Cocaine is a stimulant drug and its use is 
associated with a wide range of physical 
and mental health problems. There is a 
significant risk of toxic complications and 
sudden death, usually due to cocaine’s 
effect on the cardiovascular system.  
Cocaine use is associated with risk 
behaviour including high risk injecting and 
unsafe sex, putting users and their partners 
at significant risk of contracting a range of 
sexually transmitted diseases and bloodborne 
viruses. Cocaine effects have a rapid onset 
and can wear off relatively quickly, which 
can result in a tendency towards multiple 
use of the substance within a single session 
by users of the drug. Cocaine also produces 
strong craving, which can result from using 
the drug even just a few times, and can lead 
to severe cocaine dependence.
The risks associated with use of  
cocaine include:
 Difficulty sleeping, heart racing, headaches 
and weight loss
Numbness, tingling, clammy skin and skin 
scratching or picking
Intense craving and stress from the lifestyle 
Accidents and injury and financial problems
Mood swings – anxiety, depression and mania
Paranoia, irrational thoughts and difficulty  
remembering things
Aggressive and violent behaviour
Psychosis after repeated use of high doses
Sudden death from cardiovascular acute 
conditions
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Amphetamine-type  
stimulants (ATS)
Amphetamine-type stimulants include 
amphetamine, dexamphetamine, 
methamphetamine and ecstasy (MDMA).  
This drug class, while having some 
similar effects to cocaine, has a different 
pharmacological profile to cocaine, and use 
can lead to a wide range of physical and 
mental health problems. There is growing 
evidence that some ATS damage brain cells. 
Moreover, long term high dose amphetamine 
use is a risk factor for malnutrition which 
may also cause permanent damage to brain 
cells. There is also a high prevalence of social 
problems associated with regular ATS use 
including relationship problems, financial 
problems, work and study related problems. 
Mood swings also are associated with regular 
ATS use and some users report a worsening of 
mental health problems such as depression  
and irritability over time.
The risks associated with use of 
amphetamine-type stimulants include:
 Difficulty sleeping, loss of appetite and weight loss, 
dehydration and reduced resistance to infection
Jaw clenching, headaches and muscle pain
Mood swings –anxiety, depression, agitation, 
mania and panic
Tremors, irregular heartbeat and shortness of breath
Difficulty concentrating and remembering things
Paranoia, aggressive and violent behaviour
Psychosis after repeated use of high doses
Permanent damage to brain cells
Liver damage, brain haemorrhage and sudden 
death from cardiovascular acute conditions
Inhalants
Inhalants cover all volatile solvents that can 
be inhaled or breathed in, despite the fact 
that the substances themselves may have a 
range of different pharmacological actions. 
The most commonly used volatile substances 
include petrol, solvents, glues, sprays, lacquers 
containing benzene and glues or paint thinners 
containing toluene. Amyl nitrite and nitrous 
oxide are also used in some communities. The 
most common way they are used is to sniff 
them from a container although some may 
breathe them through a plastic bag.
The short term effects include nausea, vomiting, 
headaches, and diarrhoea. Higher doses can 
cause slurred speech, disorientation, confusion, 
delusions, weakness, tremor, headaches, and 
visual hallucinations. Ultimately use can cause 
coma or death from a heart failure.
In general, inhalants tend to be used by 
younger people for the purposes of experimen-
tation because of their ready availability, and 
use may not continue over a long period of 
time. There are some groups however who will 
use inhalants into adulthood, sometimes due 
to the lack of availability of other substances 
and cultural pressures. Inhalants tend not to 
have a high dependence liability which means 
that users are less likely, compared to other 
substances, to become dependent on them. 
However, inhalant use is associated with a 
range of severe acute and chronic effects.
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The risks associated with use of 
inhalants include:
 Flu like symptoms, sinusitis and nosebleeds
Nausea and vomiting, indigestion, stomach 
ulcers and diarrhoea
Dizziness and hallucinations, nausea, drowsi-
ness, disorientation and blurred vision
Headaches, accidents and injury, unpredictable 
and dangerous behaviour
Coordination difficulties, slowed reactions and 
poor oxygen supply to the body
Memory loss, confusion, depression, aggres-
sion and extreme tiredness
Delirium, seizures, coma and organ damage 
(heart, lungs, liver, kidneys)
Death from heart failure
Sedatives and sleeping pills
Sedatives and sleeping pills include 
benzodiazepines and related compounds 
but not neuroleptics. They are prescribed 
medicines which, however, can cause 
problems for users, particularly when used 
more frequently or at higher doses than 
prescribed. In general the ASSIST is only used 
to record problems associated with their use 
outside of the prescribed limits. Generally 
benzodiazepines are prescribed to help manage 
sleep difficulties, anxiety or mood disorders, 
trauma, surgical procedures, withdrawal from 
specific substances, seizures and muscle pain. 
Sedatives and sleeping pills include diazepam, 
temazepam, alprazolam, clonazepam, 
flunitrazepam, zolpidem, midazolam and 
phenobarbital. This is not an exhaustive list and 
only includes pharmacological names.  
Health workers administering the ASSIST 
need to become familiar with the trade 
names of these sedatives and sleeping pills 
relevant to their country. 
Tolerance and dependence on sedatives or 
sleeping pills can develop after a short period 
of use, and withdrawal from these drugs can 
be extremely unpleasant. Withdrawal symp-
toms include severe anxiety and panic, insom-
nia, depression, headache, sweating and fever, 
nausea and vomiting and convulsions.
Benzodiazepines are unlikely to cause death 
from overdose, when taken in isolation. 
However, when combined with other substanc-
es such as alcohol, paracetamol, antidepres-
sants or opioids, the risk of overdose and death 
is markedly increased.
The risks associated with use of 
sedatives and sleeping pills include:
 Drowsiness, dizziness and confusion
Difficulty concentrating and remembering things
Nausea, headaches and unsteady gait
Sleeping problems
Anxiety and depression
Tolerance and dependence after a short 
period of use
Severe withdrawal symptoms
Overdose and death if used with alcohol, 
opioids or other depressant drugs
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Hallucinogens
Hallucinogens include lysergic acid 
diethylamide (LSD), psilocybin and psilocin 
(psychoactive fungi), ketamine, phencyclidine 
(PCP) and mescaline. They are a group of 
drugs that affect the user’s perceptions of 
reality by distortion of one or several of the 
five senses (vision, hearing, smell, taste, touch) 
resulting in hallucinations. They can also result 
in distortions of cognitive processes, sense 
of time, self-awareness and mood. There 
are naturally occurring hallucinogens such 
as psychoactive fungi and mescaline, and 
synthetic hallucinogens such as LSD, ketamine 
and PCP. Ketamine is an anaesthetic drug 
but has been phased out of medical practice 
in many countries due to the nightmares 
patients experienced. Effects of hallucinogens 
are unpredictable and may be different for 
different users or on different occasions. In the 
long term, use of hallucinogens may worsen 
the symptoms of mental illnesses such as 
schizophrenia. Users may also experience 
flashbacks which are spontaneous recurrences 
of the effects of hallucinogens use in the past.
Hallucinogens tend not to have a high 
dependence liability which means that users 
are unlikely to become dependent on them, 
and they tend to be used experimentally and 
occasionally rather than repeatedly.
The risks associated with use of 
hallucinogens include:
 Visual, auditory, tactile and olfactory changes 
and unpredictable behaviour
Difficulty sleeping
Nausea and vomiting
Increased heart rate and blood pressure
Mood swings
Anxiety, panic and paranoia
Flash-backs
Worsen the symptoms of mental illnesses such 
as schizophrenia
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Opioids
Opioids are central nervous system depressants. 
There are street (non-prescribed) opioids 
such as heroin and opium, however opioids 
also can be a prescribed medicine and 
generally are used to manage pain. Use of 
street or non-prescribed opioids can cause 
many problems for users, particularly as they 
are generally injected or smoked which can 
create a further layer of problems for the user. 
Prescribed opioid use also can cause problems 
for users, particularly when used more 
frequently or at higher doses than prescribed. 
In general the ASSIST is only used to record 
problems associated with their use outside 
of the prescribed limits. Prescribed opioids 
include morphine, codeine, methadone, 
buprenorphine, pethidine (meperidine), 
dextropropoxyphene and  oxycodone. This 
is not an exhaustive list and only includes 
pharmacological names. Health workers 
administering the ASSIST need to become 
familiar with the trade names of these opioids 
relevant to their country. Opioids can be 
injected (intramuscularly, intravenously as is 
often the case with heroin), smoked (as is 
often the case with heroin and opium), taken 
orally, sub-lingually or as an anal suppository 
(pharmaceutical opioids). Injection of heroin 
results in immediate uptake of the drug and 
rapid onset of effects which can result in an 
overdose (either fatal or non-fatal), particularly 
if combined with other substances such as 
alcohol or benzodiazepines.
The risks associated with use of  
opioids include:
 Itching, nausea and vomiting
Drowsiness, constipation, tooth decay and
irregular menstrual periods
Difficulty concentrating and remembering things
Depression, reduced libido and impotence
Financial difficulties and criminal offences
Relationship stress
Problems maintaining work and family life
Tolerance, dependence and withdrawal symptoms
Overdose and death from respiratory failure
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‘Other’ drugs
‘Other’ drugs are those that do not readily 
belong in any of the other psychoactive 
substances categories pharmacologically 
or otherwise. This could include gamma 
hydroxybutyrate (GHB) and any ‘designer’ 
drugs. Other drugs such as kava, datura, khat, 
nutmeg and caffeine also may be placed in this 
category. There may be other substances used 
in other countries which don’t fit into any of 
the other substance classes given and need to  
be put into this ‘other drugs’ category.
GHB “Fantasy” was first synthesized as an 
anaesthetic and later achieved popularity as a 
recreational drug with alcohol-like properties 
and as a nutritional supplement marketed to 
bodybuilders. However, GHB was eventually 
banned as an anaesthetic in many countries 
because of its abuse potential. There were also 
reports of seizure-like activity following use. 
There is an increased risk of overdose from 
GHB compared with other drugs because the 
dose required to achieve the desirable euphoric 
effects is very close to the dose required to 
overdose. Because of its rapid onset and 
sedative/amnestic properties, GHB is allegedly 
used in ‘date rape’ cases in which the victim 
unknowingly consumes GHB in a spiked drink. 
Chronic use of GHB may produce tolerance and 
dependence and a withdrawal syndrome that is 
similar to those of alcohol and benzodiazepines 
characterised by anxiety, insomnia, tremor, 
sweating, agitation, confusion and psychosis. 
Kava is a compound derived from the roots 
of the Piper methysticum shrub which is 
cultivated on many Pacific Islands. Kava has 
been used by the people of the Pacific Islands 
for hundreds of years for ceremonial, religious, 
medicinal and social reasons. Consumed as a 
beverage, the kava root is pulverised (tradition-
ally through chewing), steeped in water and 
filtered to produce a khaki grey liquid with a 
very unpleasant taste. 
The effects of kava include numbness and tin-
gling in the mouth, mild euphoria, a reduction 
in anxiety, relaxation, sensory enhancement 
and increased sociability. At higher doses seda-
tion and incoordination occur. 
The long term effects of kava use include mild 
gastrointestinal disturbances, distortion of 
vision and a dry scaly rash appearing on the 
back of the hands, soles of feet, shins, back 
and forearms. 
Khat refers to the leaves and the young shoots 
of the plant Catha edulis native to tropical East 
Africa and the Arabian Peninsula. It contains 
an amphetamine-like stimulant which causes 
euphoria and reduces appetite. Long term use 
can cause gastrointestinal and cardiovascular 
disorders and tooth decay. 
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9 Considering the client when administering the ASSIST
The ASSIST can be administered on its own 
or combined with other questions as part of 
a general health interview, a lifestyle ques-
tionnaire, risk assessment or as a part of the 
medical history.
Clients are most likely to consent to screening 
and give accurate answers to questions about 
substance use when the health worker:
❙❙ shows that they are listening to the client;
❙❙ is friendly and non-judgemental;
❙❙ shows sensitivity and empathy towards  
the client;
❙❙ provides information about screening;
❙❙ carefully explains the reasons for asking 
about substance use;
❙❙ explains the limits of confidentiality to the client.
It may be helpful to explain that screening for 
substance use and related problems is similar 
to other screening activities such as blood pres-
sure measurement, or asking about diet and 
exercise. Linking the screening to the present-
ing complaint where it is relevant, may help 
clients to see the connection between their 
substance use and their health and make them 
more receptive to screening with the ASSIST.
Protecting the privacy of clients and the 
confidentiality of the information that 
clients provide is critical. This is especially 
important when you are collecting 
information relating to substance use. 
The use of some psychoactive substances 
is a criminal offence, or at least illegal, in 
most countries. There also is potential for 
stigmatisation and discrimination against 
those who are identified as substance users. 
Any personal information collected from 
clients must not be revealed to any individual 
or group of individuals without the client’s 
direct consent. Confidentiality is assured by 
conducting the interview in a private place 
and by keeping the ASSIST results as part 
of the confidential client record. Reassuring 
clients that the information they give will be 
confidential will also help them to provide 
accurate information about their substance 
use. However, many countries have limits 
on what kind of information can be kept as 
confidential. For example, many countries 
place an exclusion on confidentiality if a client 
divulges that they are planning or doing harm 
to themselves, someone else, or a child.
Health workers need to choose the best 
circumstances for administering the ASSIST 
and be flexible and sensitive to client needs. 
If clients are intoxicated, require emergency 
treatment or are distressed or in pain, it is 
best to wait until their medical condition has 
stabilised and they are feeling comfortable 
before administering the ASSIST. Use your clini-
cal judgement to determine the best time to 
discuss the ASSIST with each client.
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10 The ASSIST introduction
The ASSIST questionnaire comes with a set 
introduction (below). This can be read to the 
client or paraphrased by the health worker, as 
long as the health worker:
❙❙ gives the response card to the client (1 page);
❙❙ explains the list of substances and common 
terms used (see Box 3);
❙❙ explains that questions cover the last 
3 months / lifetime (see Box 4);
❙❙ explains questions are about non-prescribed 
use only;
❙❙ explains confidentiality issues.
During the introduction the health worker 
should clarify which substances are to be 
covered in the interview and ensure that they 
are referred to by names which are familiar to 
the client. The response card contains a list of 
the substance categories covered by the ASSIST 
together with a range of names associated 
with each category (see Box 3). It also contains 
frequency responses for each question (see 
Box 4). The drug names on the card are those 
which are most commonly used in the countries 
in which the ASSIST was tested, but the 
health worker should use the most culturally 
appropriate names for their location. 
The following is an illustrative introduction:
“The following questions ask about your 
experience of using alcohol, tobacco products 
and other drugs across your lifetime and in the 
past three months. These substances can be 
smoked, swallowed, snorted, inhaled or injected 
(show response card).”
“Some of the substances listed may be prescribed 
by a doctor (like amphetamines, sedatives, pain 
medications). For this interview, we will not 
record medications that are used as prescribed 
by your doctor. However, if you have taken such 
medications for reasons other than prescription, 
or taken them more frequently or at higher doses 
than prescribed, please let me know.”
“While we are also interested in knowing about 
your use of various illicit drugs, please be assured 
that information on such use will be treated as 
strictly confidential.”
For clients whose drug use is prohibited by 
law, culture or religion it may be necessary to 
acknowledge the prohibition and encourage 
honest responses about actual behaviour.  
For example, “I understand that others may 
think you should not use alcohol or other 
drugs at all but it is important in assessing your 
health to know what you actually do.”
Currently the ASSIST is only validated for use 
in an interview. Further research is needed to 
determine if it is suitable for self administration. 
However, the interview format has a number of 
advantages and can be used even when clients 
have low levels of literacy. The health worker 
can explain questions which are poorly under-
stood and can ask probing questions to clarify 
inconsistent or incomplete responses. 
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BOx 3 | Drug list for response card for clients
a Tobacco products (cigarettes, chewing tobacco, cigars, etc.)
bAlcoholic beverages (beer, wine, spirits, etc.)
c Cannabis (marijuana, pot, grass, hash, etc.)
dCocaine (coke, crack, etc.)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.)
f Inhalants (nitrous, glue, petrol, paint thinner, etc.)
g Sedatives and sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.)
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.)
j Other - specify:                
BOx 4 | Frequency responses from response card
Response card 
Last 3 months (ASSIST questions 2 to 5) 
❙❙ Never: not used in the last 3 months.
❙❙ Once or twice: 1 to 2 times in the last 
3 months.
❙❙ Monthly: average of 1 to 3 times per month 
over the last 3 months.
❙❙ Weekly: 1 to 4 times per week.
❙❙ Daily or almost daily: 5 to 7 days per week.
Response card 
Lifetime (ASSIST questions 6 to 8) 
❙❙ No, never.
❙❙ Yes, but not in the past 3 months.
❙❙ Yes, in the past 3 months.
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11 Good practice in ASSIST questionnaire administration
There are certain practices that health care 
workers can do to ensure that the correct 
scores for clients are obtained and that the 
client understands the questions that are asked 
of them. Some of these are outlined in the 
points below.
❙❙ Hold the questionnaire so the client can’t see 
what you are writing, otherwise the client’s 
response may be influenced.
❙❙ Every response for every drug and every 
question must be circled – including all zeros or 
negative responses, otherwise it may result in 
incorrect scoring.
❙❙ Remember you may need to rephrase some 
questions for some clients.
❙❙ You may need to provide prompts for some 
questions (e.g. Q4).
❙❙ Build up a picture in your mind of the client’s 
substance use and potential problems related 
to their use as they answer each subsequent 
question (especially Q2 regarding frequency 
of use in the last 3 months). Clients’ answers 
to questions that don’t seem to be consistent 
with their frequency and pattern of drug use 
should be queried further to ensure that you 
have explained the question adequately and 
that client understands the question that is 
being asked of them.
It is extremely important for health work-
ers to understand the scoring of the ASSIST 
responses to questions before first administer-
ing the questionnaire. If the client’s responses 
are not coded appropriately then the final 
resultant score may be erroneous leading 
to inappropriate feedback and a potentially 
inappropriate intervention. As shown in Box 4, 
questions 2 through 5 ask about the fre-
quency of events that have occurred in the last 
3 months. It is worth noting that:
❙❙ The last 3 months = last 12 weeks  
= last 90 days.
Using Q2 as an example How often have you 
used the substances you mentioned in the last 
3 months?, the frequencies and their associ-
ated responses mean the following:
❙❙ Never – means that the substance has not been 
used at all in the last 3 months (i.e. score = 0);
❙❙ Once or twice – means that the substance 
has been used a total of 1 to 2 times in the 
last 3 months (i.e. score = 2);
❙❙ Monthly – means the substance has been 
used an average of 1 to 3 times per month in 
the last 3 months – resulting in a total of 3 to 
9 times over the last 3 months (i.e. score = 3);
❙❙ Weekly – means the substance has been 
used an average of 1 to 4 times per week in 
the last 3 months (i.e. score = 4);
❙❙ Daily / Almost daily – means the substance 
has been used an average of 5 to 7 days per 
week in the last 3 months (i.e. score = 6).
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SELF-TESTINg | How would you code the following responses?
1 Q2. Someone who had used heroin twice in the last three months 
would be coded as… ?
2  Q2. Someone who drank alcohol every day of the week except 
Mondays in the last 3 months would be coded as… ? 
3  Q2. Someone who smoked marijuana 3 to 4 times per week in the 
last 3 months would be coded as… ?
4  Q2. Someone who uses cocaine once a fortnight would be  
coded as… ?
5 Q2. Someone who smoked cigarettes everyday but has been 
abstinent for the last 6 weeks would be coded as… ?
6 Q2. Someone who used methamphetamine 3 times in the last 
3 months would be coded as… ?
See the Appendix F to find the correct answers.
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12 How to administer the ASSIST questionnaire
The ASSIST questionnaire already contains 
some prompts and instructions to guide 
interviewers during the interview. Some of 
these instructions enable the interviewer to 
leave out some questions for some clients and 
so shorten the interview. Others remind the 
interviewer to probe for more detail to obtain 
accurate responses. While some flexibility is 
possible when asking the questions, it is impor-
tant to make sure that all the relevant ques-
tions have been asked and that the answers 
have been recorded.
Questions 1 and 2 are filter questions which 
means they determine which substances should 
be asked about in subsequent questions.
A general flow chart of how to administer the 
ASSIST is shown below in Figure 1.
FIguRE 1 | Administering the ASSIST
Q1
End
interview
Q2 Q6*, Q7* & Q8
Q3, Q4 & Q5
Calculate
score
If ‘no’ to All
If ‘yes’ to
any substance
If ‘yes’ to
any substance
If ‘never’ to All
* In Q6 & Q7 ask about all substances recorded in Q1 on lifetime use.
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Q1 In your life which of the following 
substances have you ever used 
(non-medical use only)?
(Responses = ‘yes’ or ‘no’)
Q1 asks about lifetime use of substances, i.e., 
those substances the client has ever used, 
even if it is only once. It is a good way to start 
talking to a client about their substance use 
without being too intrusive, and also gives you 
a brief history of the client’s substance use. 
Every client should be asked this question for 
all the substances listed. 
Q1 is a filter question, which means the 
answers recorded determine what happens 
next with regards to asking clients about 
specific drugs in the following questions. If 
the client answers ‘no’ to every substance in 
Q1 the health worker should ask a probing 
question “Not even when you were in 
school?” If the response is still ‘no’ to all the 
substances, then the interview is terminated. 
If the client answers ‘no’ to certain substances 
only (for example, inhalants), the health care 
worker does not ask about that substance 
(i.e., inhalants) again in the ASSIST interview.
Points to remember when asking Q1 include:
❙❙ as you are going through each substance 
group, remind the client of what that 
substance category includes (for example, 
amphetamine-type stimulants includes 
amphetamines, meth, speed and ecstasy) 
and also of any local terms for the 
substance including slang terms;
❙❙ circle ‘no’ or ‘yes’ for each substance;
❙❙ use the same terminology for substances as 
the client throughout the interview;
❙❙ give examples of ‘other drugs’ e.g. GHB, 
kava, datura and khat;
❙❙ record ‘other drug’ in the space provided;
❙❙ if a substance has never been used, don’t ask 
about it again within the context of the inter-
view (all responses for this drug will be ‘no’);
❙❙ remember Q1 is not included in scoring.
Q2 In the past 3 months how often have 
you used the substances you mentioned?
(Responses = ‘never’, ‘once or twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’)
If the client answers ‘yes’ to Q1 for any of the 
substances listed, then move on to Q2 which 
asks about substance use in the previous three 
months. Q2 should be asked only for each of 
the substances ever used (as recorded in Q1). 
Q2 also is a filter question, which means 
the answers recorded determine what hap-
pens next with regards to asking clients about 
specific drugs in the questions 3, 4 and 5. If the 
response is ‘never’ to all of the items in Q2, 
that is, no substances have been used by the 
client in the last 3 months, then move on to Q6 
which asks about substance use across the cli-
ent’s lifetime. If any substances have been used 
in the past three months then continue with 
questions 3, 4 and 5 for each substance used. 
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Points to remember when asking Q2 include:
❙❙ Ask only about the substances that client has 
reported ever using (according to Q1).
❙❙ Circle all responses, including the ‘0’ 
responses – even for drugs not used ever, 
or not used in the last 3 months.
❙❙ May need to remind client again of drug 
terms and street names.
❙❙ Remember coding definitions for the last 
3 months (i.e. ‘never’, ‘once’ or ‘twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’).
❙❙ The client may not answer using the above 
terminology (i.e. ‘never’, ‘once’ or ‘twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’) and 
you may need to calculate the appropriate 
frequency of use from the information they 
have given you (for example, a client who 
tells you that they have been smoking mari-
juana once every two weeks, you would need 
to re-interpret and score as ‘monthly’).
❙❙ All the substances that have been used in the 
last 3 months should now be asked about in 
questions 3, 4 and 5.
Q3 During the past 3 months how often 
have you had a strong desire or urge to 
use (drug)?
(Responses = ‘never’, ‘once or twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’)
Q3 reflects high risk use or dependence on 
a substance. When a client starts to use a 
substance with increasing frequency, or they 
have had past problems with the substance, 
then they may experience a strong desire 
or urge to use it. This is sometimes referred 
to as craving or hanging out by clients who 
are already dependent. It is worth noting that 
this question does not aim to record a 
mild or transient desire to use, or even 
necessarily a desire to use that is associated 
with opportunity (for example, a client who 
gets offered a drug and experiences a desire to 
use as a result, but did not have a desire to use 
before that happened). Not all clients who use 
substances will experience a strong desire to use. 
Scoring high on Q3 is generally consistent with:
❙❙ more frequent use of the substance (usually 
once a week or more), and / or;
❙❙ previous problems with the substance, and / or;
❙❙ the type of substance used (desire to use is 
closely related to the abuse and dependence 
liability of a substance, and for example, 
cocaine can produce a strong desire to use 
even only after a few uses, whereas, almost 
daily alcohol use may not produce a strong 
desire to use in absence of alcohol depend-
ence), and / or;
❙❙ injecting drugs.
The above are general pointers for helping 
to determine how to score a client on Q3, 
however, it is important to use your clinical 
judgment too, as some clients may have 
different experiences.
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Other points to remember when asking Q3 include:
❙❙ Ask only about the substances that client has 
reported using in last 3 months (according 
to Q2). Some clients may be experiencing 
a strong desire or urge to use but have not 
used the substance in the last 3 months – but 
this would not be recorded by the ASSIST. 
For example, someone who stopped smoking 
cigarettes 5 months ago, but still experiences 
a strong desire to use cigarettes would not 
be recorded on Q3 because they have not 
smoked cigarettes in the last 3 months.
❙❙ To assist clients to understand the question, 
daily use of a substance could be used to set 
a benchmark for desire to use that substance. 
For example, someone who smokes cigarettes 
everyday is very likely to be experiencing a 
strong daily desire to smoke cigarettes. The 
question could then be asked of the client, 
“You know the level of desire you experience 
for cigarettes, how often in the last 3 months 
would you have experienced a similar level of 
craving for alcohol, marijuana etc… ?”.
Q4 During the past 3 months how often 
has your use of (drug) led to health, social, 
legal or financial problems?
(Responses = ‘never’, ‘once or twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’)
Q4 on the ASSIST aims to determine if a cli-
ent’s substance use is creating any problems 
for them, and the frequency with which this 
has been happening in the last 3 months. Q4 
is only asked around substances used in the 
last 3 months (as identified in Q2). Many clients 
may not be aware of problems associated with 
their substance use, particularly health prob-
lems, and it is up to the health care worker to 
help the client link these two things together. 
This may be the first time that a client actually 
recognises and verbalises the direct impacts 
that their substance use is having on them, 
with the help of the health worker. Accordingly, 
it is worth prompting the client with examples 
of what is meant by health, social, legal and 
financial problems. A lack of prompting or 
explanation around this question could lead to 
lower scoring on this question and an overall 
erroneous score on the ASSIST. More informa-
tion about specific substance use problems can 
be found on the ASSIST feedback report card 
or in Chapter 8 of this manual. It is important 
that health workers be aware of the most com-
mon problems associated with use of specific 
substances and mentions these as examples to 
prompt clients.
For example, for tobacco using clients you 
might say, “During the past 3 months how 
often has your use of cigarettes led to any 
health, social, legal or financial problems such 
as breathlessness, finding yourself less fit than 
usual, taking longer to recover from infections 
or financial problems because you don’t have 
enough money to purchase what you need 
after buying cigarettes… ?”.
For alcohol using clients you might say, “During 
the past 3 months how often has your use of 
alcohol led to any health, social, legal or finan-
cial problems such as bad hangovers, vomiting, 
stomach pain, sleeping poorly, getting into argu-
ments with people, drink driving, doing things 
while you are drunk that you later regret… ?”.
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For cannabis using clients you might say, 
“During the past 3 months how often has your 
use of marijuana led to any health, social, legal 
or financial problems such as forgetting to do 
things, difficulty paying attention or getting 
motivated, problems getting organised, feeling 
depressed or anxious… ?”.
For clients using amphetamine-type 
stimulants you might say, “During the 
past 3 months how often has your use of 
amphetamines led to any health, social, legal 
or financial problems such as having a bad 
‘come-down’ and feeling depressed, anxious 
and irritable the day or so after you have used, 
feeling angry, aggressive or uptight, getting 
headaches, sleeping poorly, dental problems 
from grinding your teeth… ?”.
Some of the common problems that are par-
ticularly pertinent to the clients of your agency 
or organisation may not be specifically listed 
above. For example, the criminogenic impacts 
that substance use may have caused for 
offenders within a prison population, or, the 
social and familial impacts that substance use 
may have caused for clients of family and child 
health services. Health workers administering 
the ASSIST and linked brief intervention should 
be aware of the common problems associated 
with the substance use of their clientele and 
include them as examples when administering 
Q4 of the ASSIST.
Q5 During the past 3 months how often 
have you failed to do what was normally 
expected of you because of your use of 
(drug)?
(Responses = ‘never’, ‘once or twice’, 
‘monthly’, ‘weekly’, ‘daily/almost daily’)
Q5 is only asked for substances that have been 
used in the last 3 months (as identified by Q2). 
This question is designed to find out if the  
client is experiencing problems fulfilling their 
usual role obligations because of their substance 
use, which usually results in repercussions or 
consequences for the client. A failure to fulfil 
usual role obligations may result from being 
intoxicated by the substance, recovering from 
using the substance or spending all available 
time seeking the substance out (for example, 
waiting hours for a dealer and missing appoint-
ments or events that the client was expected 
to attend). You may need to prompt the client 
with examples of failed role obligations.
Common examples of role obligations that 
may not be fulfilled as a result of substance 
use include:
❙❙ missing work and losing pay or getting in 
trouble with the employer, having problems 
keeping up with work, poor work perform-
ance, negligence, losing job;
❙❙ missing school, college or university and 
falling behind, failing or doing poorly in 
assessments, or suspension or expulsion;
❙❙ failing to maintain usual family or relationship 
commitments, neglecting child caring activi-
ties, neglecting house cleaning or paying of 
bills, difficulty maintaining relationships with 
partner/friends/family or missing important 
family events.
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Tobacco is excluded from Q5 because, in 
general, people don’t fail their role obligations 
because they are smokers. 
It is worth noting that some people who are 
severely dependent on a substance may not 
have any “usual role obligations” because they 
have lost their job/family/home/support etc. 
some time ago because of their heavy and 
continued substance use. In such cases, rather 
than score these people as ‘never’, basic tasks 
such as house cleaning, feeding themselves, 
keeping appointments with doctors, welfare 
agencies etc. should be used as prompts. Such 
clients could be asked a re-phrased version of 
the question such as, “If you had responsibili-
ties and obligations, such as going to work or 
looking after your family, would you be able to 
fulfil them?” 
Q6 Has a friend or relative or anyone else 
ever expressed concern about your use of 
(drug)?
(Responses = ‘no, never’, ‘yes, in the 
past 3 months’, ‘yes, but not in the past 
3 months’)
This question is designed to find out if another 
person (e.g. family, friend, partner, spouse, 
parents, children, doctor, employer, teacher 
etc.) has expressed concern about the client’s 
substance use.
All substances that were recorded when asked 
Q1 on lifetime use must be asked about in this 
question – not just those substances used in the 
last 3 months.
You will need to turn the questionnaire back 
to the front page to see what substances have 
been used in client’s life. At first doing this may 
seem cumbersome and awkward, however, 
most health workers get used to doing this 
after administering the ASSIST a few times.
Recently expressed concern to the client’s 
substance use in the last 3 months attracts 
a higher score than concern to the client’s 
behaviour over 3 months ago. Even concern 
expressed years ago needs to be recorded in the 
‘yes, but not in the past 3 months category’.
Concern can include things such as discussion, 
questioning, nagging, advice, worry, anger etc. 
by the other party to the client.
Q7 Have you ever tried to cut down or 
stop using (drug) but failed?
(Responses = ‘no, never’, ‘yes, in the 
past 3 months’, ‘yes, but not in the past 
3 months’)
Q7 is an indicator of dependence or high risk 
use and is designed to find out about loss 
of control over substance use in the client’s 
lifetime. Substance dependence, or addiction, is 
a chronic relapsing disorder, and many people 
need to make several attempts to cut down 
or stop use before they are actually successful. 
This question investigates serious attempts 
to cut down or stop, rather than just passing 
thoughts of cutting down or half-hearted 
efforts. Usually clients scoring positive on this 
question will have been using the substance 
reasonably frequently – generally in the order 
of once a week or more, and/or at high 
concentrations (such as a heavy binge session 
on alcohol).
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A loss of control is reflected by failed attempts to 
control, cut down or stop using the substance. 
For this question unsuccessful attempts to cut 
down in the last 3 months attract the highest 
score for this question and a current problem 
with their substance use.
Clients whose last unsuccessful attempt to cut 
down was more than 3 months ago attract a 
lesser score, and indicate that the client has 
had a past problem with their substance use. 
These clients are at a greater risk of returning to 
problematic or dependent substance use than 
novice users who don’t have past problems. 
Even failed attempts to control substance use 
that occurred years ago need to be recorded as 
‘yes, but not in the past 3 months category’.
It is worth noting that successful attempts 
to cut down are not recorded. If a client has 
made several attempts to cut down and was 
successful eventually, the health worker needs 
to record the last unsuccessful attempt. For 
example, someone that successfully stopped 
smoking cigarettes 3 months ago, but had 
several failed attempts prior to that would be 
recorded as ‘yes, but not in the last 3 months’.
All substances that were recorded when asked 
Q1 on lifetime use must be asked about in this 
question – not just those substances used in the 
last 3 months.
You will need to turn the questionnaire back 
to the front page to see what substances have 
been used in client’s life. 
Clients can score 0 (‘no, never’) on this 
question for 3 reasons:
❙❙ not necessary to cut down – i.e. Don’t  
use enough;
❙❙ ‘happy’ users (pre-contemplators) – i.e. Don’t 
want to cut down;
❙❙ have successfully cut down the first time they 
tried.
Finally, because this question contains multiple 
concepts, health workers may find it helpful 
to break this question down into 3 parts. For 
example:
❙❙ Have you ever tried to cut down on smoking 
cigarettes? (‘yes’ or ‘no’)
❙❙ Were you successful? (‘yes’ or ‘no’)
❙❙ When was the last time you tried and 
weren’t successful? (‘never’ or ‘yes in the 
past 3 months’ or ‘yes, but not in the past 3 
months’)
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Q8 Have you ever used any drug by 
injection?
(Responses = ‘no, never’, ‘yes, in the 
past 3 months’, ‘yes, but not in the past 
3 months’)
This question is a possible indicator of 
dependence or high risk use and is designed 
to find out about the recency of injecting 
substance use in the client’s lifetime. Clients 
who move to injecting use are more likely to 
be or become dependent on the substance, 
depending on the frequency of use. Injecting 
is also associated with an additional range 
of harms including both fatal and non-fatal 
overdose (particularly with opioids), and 
also the risk of psychosis (particularly with 
amphetamine-type stimulants). Infections 
with bloodborne viruses are also associated 
with injecting.
While the response to question 8 does not 
contribute to the final substance scores 
achieved by the client, injecting drug use, par-
ticularly recent, is an indicator that the client 
may require further assessment and referral to 
specialised treatment for substance use.
If the client has injected drugs in the last 
3 months, you will need to do the following:
❙❙ go through risks of injecting card with client 
(Appendix D) including procedures around 
safer injecting;
❙❙ recommend that they be tested for HIV and 
hepatitis B and C;
❙❙ ascertain the frequency and pattern of 
injecting in the last 3 months for the drug 
most frequently injected. The pattern of 
injecting will assist in determining whether the 
client requires referral to specialist treatment.
Drugs most commonly injected are opioids, 
amphetamine-type stimulants, cocaine and 
sedatives such as benzodiazepines. Injection 
patterns for opioids are sometimes different 
to those for amphetamine-type stimulants and 
cocaine. While people who inject opioids tend 
to do it with some regularity, people injecting 
stimulants tend to cluster their injecting, or do 
it in runs. That is, they may inject a few days 
in a row and then have a break for a few days, 
weeks or even months before their next ses-
sion of injecting. 
As a general rule, clients injecting an 
average of more than 4 times per month 
over the last 3 months may require referral 
to specialist treatment. 
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13 Scoring of the ASSIST questionnaire
Each question on the ASSIST has a set of 
responses to choose from, and each response 
from questions 2 to 7 has a numerical score. 
The interviewer circles the numerical score 
that corresponds to the client’s response for 
each question. At the end of the interview 
the scores from questions 2 through to 7 
are added together across each individual 
substance (tobacco, alcohol, cannabis, cocaine, 
amphetamine-type stimulants, inhalants, 
sedatives/sleeping pills, hallucinogens, opioids 
and ‘other’ drugs) to produce an ASSIST risk 
score for each substance (See Box 5 for an 
example). In technical reports and papers this 
score is referred to as the specific substance 
Involvement score for each drug class.
BOx 5 | Example of calculating an 
ASSIST risk score for cannabis*
A client has given the following answers on the 
ASSIST for cannabis
Q2c Weekly Score = 4
Q3c Once/twice Score = 3
Q4c Monthly Score = 5
Q5c Once/twice Score = 5
Q6c Yes, but not in past 3 months Score = 3
Q7c No, Never Score = 0
ASSIST risk score for cannabis Total = 20
* Similar scores are calculated for all other substances used in 
the past 3 months with the exception of tobacco which does not 
include Q5 in the calculation.
For the purposes of practicality and ease, this 
is referred to as the ASSIST risk score for (drug) 
in these manuals. As laid out in the ASSIST 
questionnaire, each client will have 10 risk 
scores. That is:
aASSIST risk score for tobacco (range 0 – 31)
bASSIST risk score for alcohol (range 0 – 39)
c ASSIST risk score for cannabis (range 0 – 39)
dASSIST risk score for cocaine (range 0 – 39)
eASSIST risk score for amphetamine-type 
stimulants (range 0 – 39)
f ASSIST risk score for inhalants (range 0 – 39)
gASSIST risk score for sedatives or sleeping pills 
(range 0 – 39)
hASSIST risk score for hallucinogens  
(range 0 – 39)
i ASSIST risk score for opioids (range 0 – 39)
j ASSIST risk score for ‘other’ drugs  
(range 0 – 39).
This score can be recorded on the last page of 
the ASSIST questionnaire and the questionnaire 
kept in the client’s record if appropriate. The 
client does not see the ASSIST questionnaire 
but rather the ASSIST feedback report card 
which has the scores recorded for the client in 
an appropriate way to provide feedback as part 
of the brief intervention.
13 SCorIng of The ASSIST queSTIonnAIre ❘  33
A chance to practice
To facilitate learning around administration and 
scoring of the ASSIST, two practice examples 
(‘Dave’ and ‘Chloe’) can be found in Appendix 
G of this manual. These have been designed 
to be used in a role play with two people. The 
practice examples comprise two client scripts 
in response to the ASSIST questions. One 
person plays the role of the client and reads 
the responses (word for word) from the script. 
The other person plays the role of the health 
worker and has a blank ASSIST questionnaire 
in which to record the client’s responses. The 
resulting scores (the correct ones of which are 
found on the client’s script) are commensurate 
with the responses to the questions, and 
are found on the back page of the scripted 
examples. The script should not be altered 
or enhanced by the person role playing the 
client as this may lead to responses that don’t 
line up with the correct scoring.
The script is specifically designed to help 
health workers navigate through some of the 
common pitfalls and learn about the subtleties 
of administering the ASSIST before use with 
real clients, including:
❙❙ giving the introduction;
❙❙ asking each question accordingly, including 
prompting;
❙❙ recording the client’s response appropriately;
❙❙ learning the frequency responses;
❙❙ the use of filter questions for different drugs;
❙❙ adding up the scores for each substance and 
recording them in the box on last page;
❙❙ the use of motivational interviewing style to 
ask the questions.
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14 Interpretation of ASSIST scores
The ASSIST determines a risk score for each 
substance which is used to start a discussion 
(brief intervention) with clients about their 
substance use. The score obtained for each 
substance falls into a ‘lower’, ‘moderate’ or 
‘high’ risk category which determines the most 
appropriate intervention for that level of use 
(‘no treatment’, ‘brief intervention’ or ‘referral 
to specialist assessment and treatment’  
respectively) as per Box 6 below.
While the ASSIST provides an indication 
of the degree of substance-related risk, it 
is worth noting that there are limitations 
of making risk assessments based only 
on the ASSIST, as there are with any kind 
of psychometric tool. Substance-related 
problems are multi-faceted, and there are 
many factors which modify the risk of health 
consequences of substance use including 
family history of substance use problems, 
psychiatric comorbidity, age, gender, socio-
economic status etc. Health care workers 
should keep these factors in mind when 
estimating the actual individual risk for  
each client.
Lower risk
Clients with ASSIST Risk scores ‘three or less’ 
(‘10 or less’ for alcohol) are at a lower risk of 
problems related to their substance use. While 
they may use substances occasionally, they are 
not currently experiencing any problems related 
to their use and are at lower risk of developing 
problems related to their substance use in the 
future with their current pattern of use. 
Moderate risk
Clients scoring ‘between 4 and 26’ (‘11 and 
26’ for alcohol) are at moderate risk of health 
and other problems and may be experiencing 
some of these problems now. Continuing use in 
this way indicates a likelihood of future health 
and other problems, including the possibility of 
dependence. Risk is increased for those with  
a past history of substance use related 
problems and dependence.
High risk
A score of ‘27 or higher’ for any substance sug-
gests that the client is at high risk of depend-
ence or is dependent on that substance and is 
probably experiencing health, social, financial, 
legal and relationship problems as a result of 
their substance use. Moreover, clients who 
have injected drugs in the last three months 
more than an average of 4 times per month 
also are likely to be at high risk.
BOx 6 | What do the specific substance 
involvement scores mean?
Alcohol Allother
substances
Lower risk 0-10 0-3
Moderate risk 11-26 4-26
High risk 27+ 27+
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15 Linking ASSIST scores with treatment
The ASSIST feedback report card is completed 
at the end of the ASSIST interview and is used 
to provide personalised feedback to the client 
about their level of substance related risk. A 
good way to start the brief intervention is to 
ask the client, “Are you interested in seeing 
how you scored on the questionnaire you just 
completed?” Record the ASSIST risk scores for 
each substance in the boxes provided on the 
front of the ASSIST feedback report card. On 
the other pages record the level of risk indicat-
ed by the ASSIST risk score for all substances 
by ticking the relevant box (‘lower’, ‘moderate’ 
or ‘high’). A formatted copy of the ASSIST 
feedback report card appears in Appendix C.
The report card is used during the consultation to 
provide feedback and is given to the client to take 
home as a reminder of what has been discussed.
Lower risk
Lower risk clients should receive treatment as 
usual and can be given feedback about their 
scores if time is available. Clients who are at 
lower risk or abstainers should be encouraged 
to remain that way. For clients whose ASSIST 
score indicates that they are at lower risk of 
substance related harm for all substances this 
level of intervention is sufficient. 
Moderate risk
Moderate risk clients are ideally placed to 
receive a 3-15 minute brief intervention. The 
brief intervention comprises giving feedback 
to clients using the ASSIST feedback 
report card (Appendix C) using simple 
motivational interviewing techniques. The 
ASSIST-linked brief intervention has been 
shown to be effective in getting clients to 
significantly reduce their substance use5. 
More information on giving a simple brief 
intervention can be found in the companion 
manual ‘The ASSIST-linked brief intervention 
for hazardous and harmful substance use: 
manual for use in primary care’1. Clients 
receiving a brief intervention should also 
be given ‘Self-help strategies for cutting 
down or stopping substance use: a guide’ 25 
booklet, a copy of their ASSIST feedback 
report card, and specific drug information 
(appropriate to your country and agency) to take 
home with them. 
If clients have injected drugs in the last 
3 months, even if only once, they should 
also be provided with the risk of injecting 
card (Appendix D) which is a one page card 
that provides information and personalised 
feedback to individuals who are injecting 
drugs, including risks and problems associated 
with injecting and information around less 
risky injecting practices. The card is used 
during the brief intervention to provide advice 
and information, and is given to the client 
to take home as a reminder of what has been 
discussed. Clients should also be referred to 
a clinic where they can be tested for HIV and 
hepatitis B and C.
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High risk
The brief intervention should be given to high 
risk clients also, however, a brief intervention is 
often not feasible as a stand-alone treatment 
for high risk users. The brief intervention can 
be used in this context also to encourage 
clients to have a detailed clinical assessment 
and appropriate specialist treatment for 
their substance use. This may be provided by 
health professional(s) within that primary care 
setting, or, by a specialist drug and alcohol 
treatment service if these agencies exist and 
are accessible for the client within a reasonable 
period of time.
If specialist treatment agencies exist, staff 
should be aware of the procedures involved in 
making appointments and referral including 
waiting lists for high risk clients. If drug 
treatment facilities are not easily accessible 
or heavily stigmatised, every effort should be 
made to treat the client within the primary  
care setting.
Clients who are frequent injectors also 
should be provided with the risks of injecting 
card (Appendix D) to provide information 
and advice around injecting as part of the 
brief intervention and referral to detailed 
clinical assessment and specialist treatment.
Exceptions
Occasionally a situation may arise in which 
a client has not used a certain substance in 
the past 3 months, but still scores a ‘6’ for 
that substance, which theoretically would 
place them in the ‘moderate risk’ group. This 
situation can arise if a client, who is currently 
abstinent, has had problems with the substance 
in the past and scored a ‘3’ both on questions 
6 and 7 (‘yes, but not in the past 3 months’). 
These clients should be congratulated and 
acknowledged for their ongoing abstinence. 
It is not likely that these clients will require a 
full intervention, but should be provided 
with feedback about their scores and the 
explanation that they are in the moderate 
risk range and at increased risk because of 
their past problems with the substance, and 
accordingly need to remain vigilant.
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16 How to include screening with the ASSIST in every day practice
Screening activities such as blood pressure 
measurement, ‘pap’ smears, cholesterol 
measurement, monitoring of children’s height 
and weight and general health and welfare 
enquiries are some of the existing screening 
practices occurring in many primary health 
care settings. Screening for problems related to 
substance use and appropriate client care has 
also been widely recognised as an important 
part of good primary health care practice22, 23. 
Implementing a screening and brief 
intervention programme in your agency 
requires a commitment from management and 
staff and involves four main aspects:
❙❙ planning
❙❙ training
❙❙ monitoring
❙❙ feedback.
Planning
Planning is needed to design the screening 
programme and make sure that the processes 
fit into the special circumstances of each 
primary care practice. Ideally all staff of the 
primary health care practice should be involved 
in planning for the programme. Staff who 
are involved in planning are more likely to 
understand the reasons for the programme, 
feel a sense of ownership and enthusiasm for 
its implementation, understand their roles in 
the programme and be committed to making 
it work. Staff from different backgrounds and 
with different roles and experience will be 
able to work together to identify any possible 
difficulties and create ways to overcome them. 
It may be helpful to appoint one member of 
staff as the ASSIST coordinator. This person 
can be responsible for making sure that all staff 
understand their roles and responsibilities and 
that all of the necessary tasks are carried out. 
The plan should be clear and address all of 
the issues involved in implementing an ASSIST 
screening programme in a particular practice. 
Some of the questions which need to be 
addressed are listed in the Box 7.
BOx 7 | Implementation questions
❙❙ Which clients will be screened? 
❙❙ What is the prevalence and type of substance 
used in this setting?
❙❙ How will clients needing screening be identified?
❙❙ How often will clients be screened?
❙❙ Who will administer the ASSIST and  
brief intervention?
❙❙ When during the client’s visit will the ASSIST 
be administered?
❙❙ What follow-up actions will be taken?
❙❙ How will records of screening and follow-up 
actions be kept?
❙❙ How will copies of the ASSIST and information 
materials be obtained, stored and managed?
❙❙ How will follow-up be scheduled?
❙❙ How will you inform clients of the ASSIST 
screening programme?
❙❙ Which staff will be involved in the pro-
gramme? What will be their roles?
❙❙ What resources and processes do you have in 
the practice which will help you manage the 
screening programme?
38 ❘  ASSIST ❘  The AlCohol, SMokIng And SubSTAnCe InvolveMenT SCreenIng TeST
The plan should be comprehensive and 
ensure that screening is timely, systematic 
and efficient but should also be flexible so 
that health workers can make the most of 
unexpected opportunities for screening with 
the ASSIST. The plan that is developed also 
needs to consider the prevalence and type 
of substance use relevant to the location and 
clientele of the primary health care setting. 
For example, in a setting where injecting drug 
use may be prevalent then ready access to STD 
testing and information on less risky injecting 
practices should be available. Settings in 
which amphetamine-type stimulant use is 
common should consider having information 
on common mental health problems related to 
ATS use and access to mental health services.
There is strong evidence for the effectiveness 
of a number of strategies for implementing 
prevention and screening programmes in 
primary care. These strategies include:
❙❙ Using the waiting room to cue clients to think 
about their substance use by providing:
❙❘ posters and displays about substance 
related risks and problems;
❙❘ a well organised notice board containing 
information about the programme;
❙❘ practice newsletters;
❙❘ relevant information leaflets and client 
education material.
❙❙ Including health summary sheets in the client 
record to provide a summary of:
❙❘ particular health needs;
❙❘ whether the client has been screened 
using the ASSIST;
❙❘ their ASSIST scores and risk status;
❙❘ what interventions have been undertaken;
❙❘ when they are next due to be screened.
❙❙ Placing stickers on the client record to indi-
cate at a glance whether clients have been 
screened and when screening took place.
❙❙ Implementing reminder systems. Reminders 
can be used to: 
❙❘ invite clients to take part in the 
screening programme;
❙❘ prompt the health worker to administer 
the ASSIST during the client visit;
❙❘ invite the client for follow-up if  
needed (recall);
❙❘ remind health workers and clients when 
repeated screening is due.
If the resources are available, computerised 
information systems can be of great assistance 
in managing a screening programme.
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Training
Training of all staff involved in the screening 
programme is essential for the programme to 
be effective. Training should include:
❙❙ reading of the manuals relating to administration 
of the ASSIST and brief intervention;
❙❙ why the screening and linked intervention 
programme is important; 
❙❙ implementation procedures to be used;
❙❙ the roles and functions of staff in the screen-
ing programme and how it fits with their 
other work;
❙❙ how to administer the ASSIST and calculate 
ASSIST scores;
❙❙ how to administer the ASSIST-linked  
brief intervention;
❙❙ how to conduct follow-up activities to help 
clients at different levels of risk.
Effective training should enable staff to openly 
discuss their roles and functions and their 
attitudes to screening and early intervention 
for hazardous and harmful substance use. It 
should also provide opportunities for role play 
and supervised practice in administering the 
ASSIST and brief intervention and carrying out 
follow-up activities.*
* Some training manuals and materials in languages other than 
English are available on the WHO ASSIST website, http://www.who.
int/substance_abuse/activities/assist/en/
For information on training resources and 
training of staff please contact the WHO at:
Management of Substance Abuse, 
Department of Mental Health and 
Substance Abuse
World Health Organization
20 Avenue Appia 
1211 Geneva 27, Switzerland
Telephone: +41 22 791 3494
Fax: +41 22 791 4851
E-mail: msb@who.int
Website: www.who.int/substance_abuse/
activities/assist/en/
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Monitoring
Regular monitoring of the ASSIST screening 
programme is important to ensure that any 
implementation problems are addressed 
as they arise and to measure the success 
of the programme. There are a number 
of ways of measuring the success of a 
screening programme:
❙❙ The number of clients who have been screened 
can be compared to the number of clients 
who are eligible to be screened under the 
programme policy. This can be calculated as a 
percentage of screening success.
❙❙ The percentage of screened clients whose 
ASSIST scores indicate that they are at 
moderate or high risk can be calculated for 
each substance.
❙❙ The proportion of clients who receive the 
appropriate intervention for their ASSIST scores 
(feedback and information, brief intervention, 
more intensive treatment) can be calculated.
One of the main benefits of screening in 
primary health care is the ability to follow-up 
clients over time. It is an important aspect of 
screening to follow up those cases that are 
identified and see how they are responding 
to the intervention. An annual check up is a 
good way of approaching this. Clients who 
were screened 12 months previously and 
whose ASSIST scores indicated ‘moderate 
risk’ for substance related problems can be 
re-screened using the ASSIST to determine 
whether there has been any changes in their 
substance use behaviours. Similarly, clients 
who were screened ‘high risk’ 12 months 
previously can be reassessed to see how 
they have responded to brief interespecialist 
assessment and treatment. 
Monitoring activities cannot be carried out 
unless there are good client and programme 
records. It is important to make sure that details 
of screening and follow up interventions are 
recorded in the client record. This can be done 
using special stickers or health summary sheets. 
It is also helpful if the primary care practice 
has a central register of clients and screening 
programme activities. The ASSIST coordina-
tor should be responsible for making sure that 
appropriate records are kept.
Feedback
Frequent feedback of monitoring results to 
all participating staff is essential for ongoing 
improvement to the programme. Feedback 
also helps to maintain staff commitment to 
the programme.
Feedback from staff is also important as 
it provides information about how the 
implementation processes are working 
and enables problems to be identified and 
solutions developed.
Written reports and regular discussions 
about the ASSIST screening programme at 
staff meetings will provide opportunities for 
feedback to be given and acted upon.
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17 Guide to appendices
The attached appendices contain materials for 
both health workers and clients. These can be 
photocopied and used freely where necessary, 
in accordance with the instructions outlined in 
this manual.
Appendix A
The Alcohol, Smoking and Substance 
Involvement Screening Test (ASSIST v3.1)
The ASSIST questionnaire can be photocopied 
for repeated use in primary care and other  
treatment settings. 
Appendix B
ASSIST v3.1 response card for clients
This is a one page document which should be 
given to clients when administering the ASSIST 
in order to aid responding. The response card 
can be photocopied.
Appendix C
ASSIST v3.1 feedback report card for clients
The ASSIST feedback report card should be 
completed by the health worker with the results 
of the ASSIST and used to give feedback and 
advice to the client around their substance 
use. The client should be encouraged to take 
the card home with them. In the front you can 
find the ASSIST scores for each substance and 
risk levels followed by specific health and other 
problems associated with substance use. Health 
workers should use the ASSIST feedback report 
card in conjunction with a brief intervention.
Appendix D
ASSIST risks of injecting card for clients
This one page sheet provides advice concerning 
risks associated with injecting drugs to accom-
pany a brief intervention. This information sheet 
can be photocopied for general use in the treat-
ment setting and to give to clients who have 
injected drugs in the last 3 months. 
Clients who are high risk injectors (injecting four 
times per month or more in the last 3 months) 
may also find this card helpful, but will require 
more intensive treatment.
Appendix E
Translation and adaptation to local 
languages and culture: a resource for 
clinicians and researchers
This resource sets out the guidelines by which 
the ASSIST and related materials must be 
translated. There are some versions of the 
ASSIST available on the website (http://www.
who.int/substance_abuse/activities/assist/en/) 
in languages other than English. Please contact 
the WHO for support and registration if you are 
planning to translate the ASSIST materials or 
resources into your language:
Management of Substance Abuse, 
Department of Mental Health and 
Substance Abuse
World Health Organization
20 Avenue Appia 
1211 Geneva 27, Switzerland
Telephone: +41 22 791 3494
Fax: +41 22 791 4851
E-mail: msb@who.int
Website: www.who.int/substance_abuse/
activities/assist/en/
Appendix F
Answers to self-testing questions  from 
Chapter 11 on ‘Good Practice in ASSIST ques-
tionnaire administration’.
Appendix g
Two client scripts (‘Chloe’ and ‘Dave’) to be 
used in role plays with two people (one playing 
health worker and one playing client) to practice 
using the ASSIST and getting the administration 
and scores correct, before use with actual clients.
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Appendix A
The Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST v3.1)
Introduction (please read to client or adapt for local circumstances)*
The following questions ask about your experience of using alcohol, tobacco products and other 
drugs across your lifetime and in the past three months. These substances can be smoked, swal-
lowed, snorted, inhaled or injected (show response card).
Some of the substances listed may be prescribed by a doctor (like amphetamines, sedatives, pain 
medications). For this interview, we will not record medications that are used as prescribed by 
your doctor. However, if you have taken such medications for reasons other than prescription, or 
taken them more frequently or at higher doses than prescribed, please let me know. 
While we are also interested in knowing about your use of various illicit drugs, please be assured 
that information on such use will be treated as strictly confidential.
Before asking questions, give ASSIST response card to client
QuESTION 1 | In your life, which of the following substances have you ever used 
(non-medical use only)? 
a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) No Yes
bAlcoholic beverages (beer, wine, spirits, etc.) No Yes
c Cannabis (marijuana, pot, grass, hash, etc.) No Yes
dCocaine (coke, crack, etc.) No Yes
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) No Yes
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) No Yes
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.) No Yes
h Hallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) No Yes
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) No Yes
j Other – specify:                No Yes
Probe if all answers are negative:  
“Not even when you were in school?”
If “No” to all items, stop interview.
If “Yes” to any of these items, ask Q2 for each 
substance ever used
* ASSIST V3.1 is to be utilized by for screening in clinical settings. For research purposes please use the previous version ASSIST V3.0. 
© World Health Organization 2010
Clinician Name  Clinic
Client ID or Name Date
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QuESTION 2 | In the past three months, how often 
have you used the substances you mentioned (first 
drug, second drug, etc)?
N
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a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 2 3 4 6
b Alcoholic beverages (beer, wine, spirits, etc.) 0 2 3 4 6
c Cannabis (marijuana, pot, grass, hash, etc.) 0 2 3 4 6
d Cocaine (coke, crack, etc.) 0 2 3 4 6
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 2 3 4 6
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 2 3 4 6
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.)
0 2 3 4 6
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 2 3 4 6
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 2 3 4 6
j Other – specify:                0 2 3 4 6
If “Never” to all items in Q2, skip to Q6.
If any substances in Q2 were used in the previous three months, continue with Questions 3, 4 & 5 for each 
substance used.
QuESTION 3 | During the past three months, how 
often have you had a strong desire or urge to use 
(first drug, second drug, etc)?
N
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a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 4 5 6
bAlcoholic beverages (beer, wine, spirits, etc.) 0 3 4 5 6
c Cannabis (marijuana, pot, grass, hash, etc.) 0 3 4 5 6
dCocaine (coke, crack, etc.) 0 3 4 5 6
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 3 4 5 6
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 4 5 6
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.)
0 3 4 5 6
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 3 4 5 6
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 3 4 5 6
j Other – specify:                0 3 4 5 6
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QuESTION 4 | During the past three months, how 
often has your use of (first drug, second drug, etc) led 
to health, social, legal or financial problems?
N
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a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 4 5 6 7
bAlcoholic beverages (beer, wine, spirits, etc.) 0 4 5 6 7
c Cannabis (marijuana, pot, grass, hash, etc.) 0 4 5 6 7
dCocaine (coke, crack, etc.) 0 4 5 6 7
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 4 5 6 7
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 4 5 6 7
gSedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
0 4 5 6 7
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 4 5 6 7
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 4 5 6 7
j Other – specify:                0 4 5 6 7
QuESTION 5 | During the past three months, how 
often have you failed to do what was normally 
expected of you because of your use of (first drug, 
second drug, etc)? Ne
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a Tobacco products
bAlcoholic beverages (beer, wine, spirits, etc.) 0 5 6 7 8
c Cannabis (marijuana, pot, grass, hash, etc.) 0 5 6 7 8
dCocaine (coke, crack, etc.) 0 5 6 7 8
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 5 6 7 8
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 5 6 7 8
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, 
midazolam, etc.)
0 5 6 7 8
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 5 6 7 8
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 5 6 7 8
j Other – specify:                0 4 5 6 7
Ask questions 6 & 7 for all substances ever used (i.e. those endorsed in Q1).
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QuESTION 6 | Has a friend or relative or anyone else ever 
expressed concern about your use of (first drug, second drug, etc)?
N
o,
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a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3
bAlcoholic beverages (beer, wine, spirits, etc.) 0 6 3
c Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3
d Cocaine (coke, crack, etc.) 0 6 3
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 6 3
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, 
etc.)
0 6 3
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 6 3
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 6 3
j Other – specify:                0 6 3
Ask questions 6 & 7 for all substances ever used (i.e. those endorsed in Q1).
QuESTION 7 | Have you ever tried to cut down on using (first 
drug, second drug, etc) but failed?
N
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a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3
bAlcoholic beverages (beer, wine, spirits, etc.) 0 6 3
c Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3
d Cocaine (coke, crack, etc.) 0 6 3
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) 0 6 3
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, 
etc.)
0 6 3
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) 0 6 3
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) 0 6 3
j Other – specify:                0 6 3
Ask questions 6 & 7 for all substances ever used (i.e. those endorsed in Q1).
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QuESTION 8 | Have you ever used any drug by injection 
(non-medical use only)?
N
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(Please tick the appropriate box)
IMPORTANT NOTE
Clients who have injected drugs in the last 3 months should be asked about their pattern of injecting during 
this period, to determine their risk levels and the best course of intervention.
Pattern of injecting Intervention guidelines
4 days per month, on average, over the 
last 3 months or less
Brief intervention including the risks of 
injecting card
More than 4 days per month, on  
average, over the last 3 months
Further assessment and more intensive 
treatment
How to calculate a specific substance involvement score.
For each substance (labelled ‘a’ to ‘j’) add up the scores received for questions 2 through 7 inclusive. 
Do not include the results from either Q1 or Q8 in this score. For example, a score for cannabis 
would be calculated as: Q2c + Q3c + Q4c + Q5c + Q6c + Q7c.
APPendIx A ❘  The AlCohol, SMokIng And SubSTAnCe InvolveMenT SCreenIng TeST (ASSIST v3.1) ❘  47
Note that Q5 for tobacco is not coded, and is calculated as: Q2a + Q3a + Q4a + Q6a + Q7a.
The type of intervention is determined by the patient’s specific substance involvement score
Record 
specific 
substance 
score
No 
intervention
Receive brief 
intervention
More 
intensive 
treatment
a Tobacco 0 – 3 4 – 26 27+
bAlcohol 0 – 10 11 – 26 27+
c Cannabis 0 – 3 4 – 26 27+
dCocaine 0 – 3 4 – 26 27+
e ATS 0 – 3 4 – 26 27+
f Inhalants 0 – 3 4 – 26 27+
g Sedatives 0 – 3 4 – 26 27+
hHallucinogens 0 – 3 4 – 26 27+
i Opioids 0 – 3 4 – 26 27+
j Other drugs 0 – 3 4 – 26 27+
Now use ASSIST feedback report card to give client brief intervention.
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Appendix B
ASSIST v3.1 response card
RESPONSE CARD | Substances
a Tobacco products (cigarettes, chewing tobacco, cigars, etc.)
bAlcoholic beverages (beer, wine, spirits, etc.)
c Cannabis (marijuana, pot, grass, hash, etc.)
dCocaine (coke, crack, etc.)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.)
f Inhalants (nitrous, glue, petrol, paint thinner, etc.)
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.)
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.)
j Other – specify:                
RESPONSE CARD | Frequency responses
Response card 
Last 3 months (ASSIST questions 2 to 5) 
❙❙ Never: not used in the last 3 months.
❙❙ Once or twice: 1 to 2 times in the last 
3 months.
❙❙ Monthly: average of 1 to 3 times per month 
over the last 3 months.
❙❙ Weekly: 1 to 4 times per week.
❙❙ Daily or almost daily: 5 to 7 days per week.
Response card 
Lifetime (ASSIST questions 6 to 8) 
❙❙ No, never.
❙❙ Yes, but not in the past 3 months.
❙❙ Yes, in the past 3 months.
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Appendix C
ASSIST v3.1 feedback report card
Specific substance involvement scores Score RiskLevel
a Tobacco products
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
bAlcoholic beverages
0 – 10 
11 – 26 
27+
Lower 
Moderate 
High
c Cannabis
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
dCocaine
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
e Amphetamine-type stimulants
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
f Inhalants
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
g Sedatives or sleeping pills
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
hHallucinogens
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
i Opioids
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
j Other – specify:                
0 – 3 
4 – 26 
27+
Lower 
Moderate 
High
What do your scores mean?
Lower: You are at lower risk of health and other problems from your current pattern of use.
Moderate: You are at moderate risk of health and other problems from your current pattern of 
substance use.
High: You are at high risk of experiencing severe problems (health, social, financial, legal, relationship) as 
a result of your current pattern of use and are likely to be dependent.
Client ID or Name  Date
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A | Tobacco
Your risk of experiencing these harms is (tick one): 
Lower Moderate High
Regular tobacco smoking is associated with:
Premature ageing and wrinkling of the skin
Low fitness and longer recovery times after 
having a cold or flu
Respiratory infections and asthma
High blood pressure and diabetes mellitus
Miscarriage, premature labour and low birth 
weight babies for pregnant women
Kidney disease
Chronic obstructive pulmonary diseases 
including emphysema
Heart disease, stroke and vascular diseases
Cancers of lung, bladder, breast, mouth, 
throat and oesophagus
B | Alcohol
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular exessive alcohol use is associated with:
 Hangovers, aggressive and violent behaviour, 
accidents and injury, nausea and vomiting
Reduced sexual performance and  
premature ageing
Digestive problems, ulcers, inflammation of 
the pancreas and high blood pressure
Anxiety and depression, relationship difficulties, 
and financial and work problems
Difficulty remembering things and  
solving problems
Birth defects and brain damage in babies of 
pregnant women
Permanent brain damage leading to memory 
loss, cognitive deficits and disorientation
Stroke, muscle and nerve damage
Liver and pancreas diseases
Cancers of the mouth, throat and breast
Suicide
Are you concerned about your substance use?
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E | Amphetamine-type stimulants
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of amphetamine-type stimulants  
is associated with:
 Difficulty sleeping, loss of appetite and weight loss, 
dehydration and reduced resistance to infection
Jaw clenching, headaches and muscle pain
Mood swings –anxiety, depression, agitation, 
mania and panic
Tremors, irregular heartbeat and shortness of breath
Difficulty concentrating and remembering things
Paranoia, aggressive and violent behaviour
Psychosis after repeated use of high doses
Permanent damage to brain cells
Liver damage, brain haemorrhage and sudden 
death from cardiovascular acute conditions
F | Inhalants
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of inhalant is associated with:
 Flu like symptoms, sinusitis and nosebleeds
Nausea and vomiting, indigestion, stomach 
ulcers and diarrhoea
Dizziness and hallucinations, nausea, drowsi-
ness, disorientation and blurred vision
Headaches, accidents and injury, unpredictable 
and dangerous behaviour
Coordination difficulties, slowed reactions and 
poor oxygen supply to the body
Memory loss, confusion, depression, aggression 
and extreme tiredness
Delirium, seizures, coma and organ damage 
(heart, lungs, liver, kidneys)
Death from heart failure
C | Cannabis
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of cannabis is associated with:
 Problems with attention and motivation
Anxiety, paranoia, panic and depression
Decreased memory and problem solving ability
High blood pressure
Asthma and bronchitis
Psychotic symptoms and psychoses particularly 
in those with a personal or family history of 
schizophrenia
Heart disease and chronic obstructive pul-
monary disease
Cancers of the upper airway and throat
D | Cocaine
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of cocaine is associated with:
 Difficulty sleeping, heart racing, headaches 
and weight loss
Numbness, tingling, clammy skin and skin 
scratching or picking
Intense craving and stress from the lifestyle
Accidents and injury and financial problems
Mood swings – anxiety, depression and mania
Paranoia, irrational thoughts and difficulty  
remembering things
Aggressive and violent behaviour
Psychosis after repeated use of high doses
Sudden death from cardiovascular acute 
conditions
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g | Sedatives or sleeping pills
Your risk of experiencing these harms is (tick one):
Lower  Moderate High
Regular use of sedatives is associated with:
 Drowsiness, dizziness and confusion
Difficulty concentrating and remembering things
Nausea, headaches and unsteady gait
Sleeping problems
Anxiety and depression
Tolerance and dependence after a short 
period of use
Severe withdrawal symptoms
Overdose and death if used with alcohol, 
opioids or other depressant drugs
H | Hallucinogens
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of hallucinogens is associated with:
 Visual, auditory, tactile and olfactory changes 
and unpredictable behaviour
Difficulty sleeping
Nausea and vomiting
Increased heart rate and blood pressure
Mood swings
Anxiety, panic and paranoia
Flash-backs
Worsen the symptoms of mental illnesses such 
as schizophrenia
I | Opioids
Your risk of experiencing these harms is (tick one):
Lower Moderate High
Regular use of opioids is associated with:
 Itching, nausea and vomiting
Drowsiness, constipation, tooth decay and
irregular menstrual periods
Difficulty concentrating and remembering things
Depression, reduced libido and impotence
Financial difficulties and criminal offences
Relationship stress
Problems maintaining work and family life
Tolerance, dependence and withdrawal symptoms
Overdose and death from respiratory failure
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Appendix D
ASSIST risks of injecting card ❘ Information for clients
using substances by injection 
increases the risk of harm from 
substance use
This harm can come from:
❙❙ The substance:
❙❘ If you inject any drug you are more likely 
to become dependent.
❙❘ If you inject amphetamines or cocaine you 
are more likely to experience psychosis.
❙❘ If you inject heroin or other sedatives you 
are more likely to overdose.
❙❙ The injecting behaviour:
❙❘ If you inject you may damage your skin 
and veins and get infections.
❙❘ You may cause scars, bruises, swelling, 
abscesses and ulcers. 
❙❘ Your veins might collapse.
❙❘ If you inject into the neck you can cause 
a stroke.
❙❙ Sharing of injecting equipment:
❙❘ If you share injecting equipment (needles & 
syringes, spoons, filters, etc.) you are more 
likely to spread bloodborne virus infections 
like hepatitis B and C and HIV.
It is less risky not to inject
If you do inject:
❙❘ always use clean equipment (e.g., needles 
& syringes, spoons, filters, etc.)
❙❘ always use a new needle and syringe
❙❘ don’t share equipment with other people
❙❘ clean the preparation area
❙❘ clean your hands
❙❘ clean the injecting site
❙❘ use a different injecting site each time 
❙❘ inject slowly
❙❘ put your used needle and syringe in a hard 
container and dispose of it safely.
❙❙ If you use stimulant drugs like amphetamines 
or cocaine the following tips will help you 
reduce your risk of psychosis:
❙❘ avoid injecting and smoking
❙❘ avoid using on a daily basis.
❙❙ If you use depressant drugs like heroin the 
following tips will help you reduce your risk 
of overdose:
❙❘ avoid using other drugs, especially seda-
tives or alcohol, on the same day
❙❘ use a small amount and always have a trial 
“taste” of a new batch
❙❘ have someone with you when you are using
❙❘ avoid injecting in places where no-one can 
get to you if you do overdose
❙❘ know the telephone numbers of the 
ambulance service.
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Appendix E
Translation and adaptation to local languages and culture: 
a resource for clinicians and researchers
The ASSIST instrument, instructions, drug 
cards, response scales and resource manuals 
may need to be translated into local languages 
for use in particular countries or regions. 
Translation from English should be as direct as 
possible to maintain the integrity of the tools 
and documents. However, in some cultural 
settings and linguistic groups, aspects of the 
ASSIST and its companion documents may 
not be able to be translated literally and there 
may be socio-cultural factors that will need to 
be taken into account in addition to seman-
tic meaning. In particular, substance names 
may require adaptation to conform to local 
conditions, and it is also worth noting that the 
definition of a standard drink may vary from 
country to country.
Translation should be undertaken by a bilingual 
translator, preferably a health professional 
with experience in interviewing. For the 
ASSIST instrument itself, translations should be 
reviewed by a bilingual expert panel to ensure 
that the instrument is not ambiguous. Back 
translation into English should then be carried 
out by another independent translator whose 
main language is English to ensure that no 
meaning has been lost in the translation. This 
strict translation procedure is critical for the 
ASSIST instrument to ensure that comparable 
information is obtained wherever the ASSIST is 
used across the world.
Translation of this manual and companion 
documents may also be undertaken if 
required. These do not need to undergo the 
full procedure described above, but should 
include an expert bilingual panel.
Before attempting to translate the ASSIST 
and related documents into other languages, 
interested individuals should consult with the 
WHO about the procedures to be followed 
and the availability of other translations. 
Contact WHO at:
Management of Substance Abuse, 
Department of Mental Health and 
Substance Abuse
World Health Organization
20 Avenue Appia 
1211 Geneva 27, Switzerland
Telephone: +41 22 791 3494
Fax: +41 22 791 4851
E-mail: msb@who.int
Website: www.who.int/substance_abuse/
activities/assist/en/
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Appendix F
Answers to self-testing questions from Chapter 11
SELF-TESTINg | Answers
1 Q2. Someone who had used heroin twice in the last three months 
would be coded as… ?
Once or twice = 2
2  Q2. Someone who drank alcohol every day of the week except 
Mondays in the last 3 months would be coded as… ? 
Daily/almost daily = 6
3  Q2. Someone who smoked marijuana 3 to 4 times per week in the 
last 3 months would be coded as… ?
Weekly = 4
4  Q2. Someone who uses cocaine once a fortnight would be  
coded as… ?
Monthly = 3
5 Q2. Someone who smoked cigarettes everyday but has been 
abstinent for the last 6 weeks would be coded as… ?
Weekly = 4
6 Q2. Someone who used methamphetamine 3 times in the last 
3 months would be coded as… ?
Monthly = 3
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Appendix G
Two client scripts (‘Chloe‘ and ‘Dave‘)
Instructions for paired role play
This paired role-play can be used to help you practice correct administration of the ASSIST. It is also 
a valuable exercise to help you understand what it is like for a client to be administered the ASSIST 
questionnaire. Two people are required for the activity; one person to play the interviewer, and one 
person to play the client. You will also need the ASSIST v3.1 questionnaire and ASSIST response 
card for this activity. 
The person who is administering the ASSIST questionnaire (interviewer) uses a blank ASSIST ques-
tionnaire to record the client’s responses. The ASSIST introduction, which is provided on the front 
page of the ASSIST questionnaire, should also read or paraphrased as part of the role-play, and the 
ASSIST response card given to the client. 
The person who is playing the client reads this script in response to interviewer’s questions. 
The script must be read as written, as any changes may result in erroneous coding and 
scoring by interviewer.
Following administration of the ASSIST questionnaire, the interviewer should calculate the client’s 
final scores and record them in the box on the last page of the ASSIST v3.1 questionnaire. The 
scores calculated by the interviewer should be compared with the correct scores provided on the 
back page of this script. If there are any differences, they should be discussed and resolved by the 
role-play pair, so that the final scores obtained by the interviewer reflect the scores provided on 
this script.
NOTE TO PERSON READINg CLIENT SCRIPT
Some of your responses have brackets around them (e.g. Q2d.). This means that the interviewer 
should not have asked you this question due to filtering out. The answer written in brackets may 
still be provided to the interviewer, along with feedback to remind them that they did not need 
to ask you this question.
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QuESTION 1 | In your life, which of the following substances have you ever used 
(non-medical use only)? 
a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) Yes
bAlcoholic beverages (beer, wine, spirits, etc.) Yes
c Cannabis (marijuana, pot, grass, hash, etc.) Yes
dCocaine (coke, crack, etc.) No
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Yes
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Yes
gSedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.) Yes
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) No
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) No
j Other – specify:                No
QuESTION 2 | In the past three months, how often have you used the substances you 
mentioned (first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Every day
bAlcoholic beverages (beer, wine, spirits, etc.) Every day
c Cannabis (marijuana, pot, grass, hash, etc.) Once or twice
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) About once a week
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) I’ve used nitrous oxide twice
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
Haven’t used them in the last 3 months
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
Client script ASSIST v3.1 (Chloe) 
Responses for paired role play
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QuESTION 3 | During the past three months, how often have you had a strong desire 
or urge to use (first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Every day
bAlcoholic beverages (beer, wine, spirits, etc.) I’ve had some desire to drink but I 
wouldn’t say a strong desire so I would 
have to say never in the last 3 months
c Cannabis (marijuana, pot, grass, hash, etc.) Never
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Probably have had a really strong crav-
ing for speed once or twice in the last 
3 months
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Never
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Haven’t used them in last 3 months)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
QuESTION 4 | During the past three months, how often has your use of 
(first drug, second drug, etc) led to health, social, legal or financial problems?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Once or twice in the last 3 months 
I’ve noticed that I have been really out 
of breath after exercise and I think its 
because of smoking
bAlcoholic beverages (beer, wine, spirits, etc.) I’ve had really bad hangovers on average 
about once every fortnight in the last 
3 months
c Cannabis (marijuana, pot, grass, hash, etc.) Never
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) I’ve run out of money twice in the last 
three months because of buying speed and 
I’ve had some problems paying my bills
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Never
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Haven’t used them in last 3 months)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
APPendIx g ❘  ClIenT SCrIPT ASSIST v3.1 (Chloe)reSPonSeS for PAIred role PlAy ❘  59
QuESTION 5 | During the past three months, how often have you failed to do what was 
normally expected of you because of your use of (first drug, second drug, etc)?
a Tobacco products
bAlcoholic beverages (beer, wine, spirits, etc.) Never
c Cannabis (marijuana, pot, grass, hash, etc.) Never
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Never
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Never
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Haven’t used them in last 3 months)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
QuESTION 6 | Has a friend or relative or anyone else ever expressed concern about 
your use of (first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Yes, my doctor said I should stop smok-
ing about a year ago, but not since then
bAlcoholic beverages (beer, wine, spirits, etc.) Yes, but not in  
the past 3 months
c Cannabis (marijuana, pot, grass, hash, etc.) Never
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Yes, my boyfriend did  
last month
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Never
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
Yes, but not in  
the past 3 months
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
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QuESTION 7 | Have you ever tried to cut down on using (first drug, second drug, etc) 
but failed?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Yes, I’ve tried in the last 3 months but I 
haven’t been successful
bAlcoholic beverages (beer, wine, spirits, etc.) Never tried
c Cannabis (marijuana, pot, grass, hash, etc.) Never
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Never
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) Never
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
I used to use a lot of Valium and had to cut 
down on it but I was successful the first time
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) (Never tried hallucinogens)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Never tried opioids)
j Other – specify:                (Never tried other drugs)
QuESTION 8 | Have you ever used any drug by injection  
(non-medical use only)?
Never
The type of intervention is determined by the patient’s specific substance involvement score
Recordspecific
substance
score
No
intervention
Receivebrief
intervention
Moreintensive
treatment
a Tobacco 25 0 – 3 4 – 26 27+
bAlcohol 14 0 – 10 11 – 26 27+
c Cannabis 2 0 – 3 4 – 26 27+
dCocaine 0 0 – 3 4 – 26 27+
e ATS 17 0 – 3 4 – 26 27+
f Inhalants 2 0 – 3 4 – 26 27+
g Sedatives 3 0 – 3 4 – 26 27+
hHallucinogens 0 0 – 3 4 – 26 27+
i Opioids 0 0 – 3 4 – 26 27+
j Other drugs 0 0 – 3 4 – 26 27+
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Role play Chloe’s scoring
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Total
a Tobacco Yes
Daily 
6
Daily 
6
O-T 
4
NA
Y/N 3m 
3
Y 3m 
6
25
bAlcohol Yes
Daily 
6
Never 
0
Monthly 
5
Never 
0
Y/N 3m 
3
Never 
0
14
c Cannabis Yes
O-T 
2
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
2
dCocaine No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
e ATS Yes
Weekly 
4
O-T 
3
O-T 
4
Never 
0
Y 3m 
6
Never 
0
17
f Inhalants Yes
O-T 
2
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
2
g Sedatives Yes
Never 
0
Never 
0
Never 
0
Never 
0
Y/N 3m 
3
Never 
0
3
h Hallucinogens No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
i Opioids No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
j Other drugs No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
IMPORTANT NOTE
‘Y/N 3m‘ means; “Yes, but not in the past 3 months” (score of 3).
‘O-T‘ means; “Once or Twice”.
‘Y 3m‘ means; “Yes, in the past 3 months” (score of 6).
Q1 and Q8 are not included in the scoring.
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Client script WHO ❘ ASSIST v3.1 (Dave)
Responses for paired role play
QuESTION 1 | In your life, which of the following substances have you ever used 
(non-medical use only)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc.) Yes
bAlcoholic beverages (beer, wine, spirits, etc.) Yes
c Cannabis (marijuana, pot, grass, hash, etc.) Yes
dCocaine (coke, crack, etc.) No
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Yes
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) No
g Sedatives or sleeping pills (diazepam, alprazolam, flunitrazepam, midazolam, etc.) No
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Yes
i Opioids (heroin, morphine, methadone, buprenorphine, codeine, etc.) Yes
j Other – specify:                Yes, I’ve 
tried kava
QuESTION 2 | In the past three months, how often have you used the substances you 
mentioned (first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Every day
bAlcoholic beverages (beer, wine, spirits, etc.) Once or twice
c Cannabis (marijuana, pot, grass, hash, etc.) Pretty much every day
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Not in the last 3 months
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips,  
ketamine, etc.)
I’ve had a couple trips in the last 
3 months (twice)
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
I used to be addicted to heroin and made 
several attempts to cut down, but I man-
aged to stop using completely about 3 
years ago – so I haven’t used any opioids 
in the last 3 months
j Other – specify: kava Only tried kava once years ago, haven’t 
used since
APPendIx g ❘  ClIenT SCrIPT Who ❘  ASSIST v3.1 (dAve)reSPonSeS for PAIred role PlAy ❘  63
QuESTION 3 | During the past three months, how often have you had a strong desire 
or urge to use(first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Every day
bAlcoholic beverages (beer, wine, spirits, etc.) Never
c Cannabis (marijuana, pot, grass, hash, etc.) Every day 
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) (Haven’t used last 3 months)
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Never
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Haven’t used last 3 months)
j Other – specify: kava (Haven’t used last 3 months)
QuESTION 4 | During the past three months, how often has your use of (first drug, 
second drug, etc) led to health, social, legal or financial problems?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) I wake up with a really bad cough once 
or twice a week. I’ve been like that for 
about 2 years
bAlcoholic beverages (beer, wine, spirits, etc.) Never
c Cannabis (marijuana, pot, grass, hash, etc.) Last month the police gave me a caution 
for possessing marijuana, but nothing 
else really
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) (Haven’t used last 3 months)
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Never
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Haven’t used last 3 months)
j Other – specify: kava (Haven’t used last 3 months)
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QuESTION 5 | During the past three months, how often have you failed to do what 
was normally expected of you because of your use of (first drug, second drug, etc)?
a Tobacco products
bAlcoholic beverages (beer, wine, spirits, etc.) Never
c Cannabis (marijuana, pot, grass, hash, etc.) Two months ago I forgot to attend an 
important family event because I was 
smoking marijuana all day. My family 
were very angry at me because of it.
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) (Haven’t used last 3 months)
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Never
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
(Haven’t used last 3 months)
j Other – specify: kava (Haven’t used last 3 months)
QuESTION 6 | Has a friend or relative or anyone else ever expressed concern about 
your use of (first drug, second drug, etc)?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Yes, but not in the past 3 months
bAlcoholic beverages (beer, wine, spirits, etc.) Never
c Cannabis (marijuana, pot, grass, hash, etc.) Yes, about 6 months ago
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Never
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Never
i Opioids (heroin, morphine, methadone, buprenorphine, 
codeine, etc.)
Yes, but it was years ago
j Other – specify: kava Never
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QuESTION 7 | Have you ever tried to cut down on using (first drug, second drug, etc) 
but failed?
a Tobacco products (cigarettes, chewing tobacco, cigars, etc) Yes, I tried last month but failed
bAlcoholic beverages (beer, wine, spirits, etc.) Never had to 
c Cannabis (marijuana, pot, grass, hash, etc.) I’ve never tried to stop
dCocaine (coke, crack, etc.) (Never tried coke)
e Amphetamine-type stimulants (speed, meth, ecstasy, etc.) Never been a problem
f Inhalants (nitrous, glue, petrol, paint thinner, etc.) (Never tried inhalants)
g Sedatives or sleeping pills (diazepam, alprazolam, 
flunitrazepam, midazolam, etc.)
(Never tried sedatives)
hHallucinogens (LSD, acid, mushrooms, trips, ketamine, etc.) Never had to
i Opioids (heroin, morphine, methadone, buprenorphine,  
codeine, etc.)
Yes, but not in the  
past 3 months
j Other – specify: kava Only used once, so no never
QuESTION 8 | Have you ever used any drug by injection  
(non-medical use only)?
Yes, but not in the past 3 months
The type of intervention is determined by the patient’s specific substance involvement score
Recordspecific
substance
score
No
intervention
Receivebrief
intervention
Moreintensive
treatment
a Tobacco 27 0 – 3 4 – 26 27+
bAlcohol 2 0 – 10 11 – 26 27+
c Cannabis 24 0 – 3 4 – 26 27+
dCocaine 0 0 – 3 4 – 26 27+
e ATS 0 0 – 3 4 – 26 27+
f Inhalants 0 0 – 3 4 – 26 27+
g Sedatives 0 0 – 3 4 – 26 27+
hHallucinogens 2 0 – 3 4 – 26 27+
i Opioids 6 0 – 3 4 – 26 27+
j Other drugs 0 0 – 3 4 – 26 27+
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Role play Dave’s scoring
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Total
a Tobacco Yes
Daily 
6
Daily 
6
Weekly 
6
NA
Y/N 3m
3
Y 3m
6
27
bAlcohol Yes
O-T 
2
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
2
c Cannabis Yes
Daily 
6
Daily 
6
O-T 
4
O-T 
5
Y/N 3m
3
Never 
0
24
dCocaine No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
e ATS Yes
Never 
0
Never 
0
Never 
0
Never 
0
Never
0
Never 
0
0
f Inhalants No
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
g Sedatives No
Never 
0
Never 
0
Never 
0
Never 
0
Never
0
Never 
0
0
hHallucinogens Yes
O-T 
2
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
2
i Opioids Yes
Never 
0
Never 
0
Never 
0
Never 
0
Y/N 3m
3
Y/N 3m 
3
6
j Other drugs Yes
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
Never 
0
0
IMPORTANT NOTE
‘Y/N 3m‘ means; “Yes, but not in the past 3 months” (score of 3).
‘O-T‘ means; “Once or Twice”.
‘Y 3m‘ means; “Yes, in the past 3 months” (score of 6).
Q1 and Q8 are not included in the scoring.
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